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Cancer is the leading cause of death worldwide, accounting for an estimated 7.6 
million deaths in 2008 [1]. Breast cancer is the most common type of cancer in women for 
both developed and developing countries. The effectiveness of anti-hormonal treatment of 
early breast cancer can be attributed to the fact that approximately two-thirds of breast 
tumors are hormone-dependent and require growth factors like estrogen to grow [2]. There 
is some different type of systemic therapy for breast cancer, one kind is hormonal therapy. 
Hormonal therapy can be given to women whose breast cancers test positive for estrogen to 
lower estrogen levels. Letrozole is a third generation of non-steroidal aromatase inhibitor – 
one class of hormonal therapy drugs- that was first introduces by Novartis to the market as 
Femara ® for the treatment of local or metastatic breast cancer [3-5]. 
It is well known that compounds having an aza-hetero ring, such as triazole show 
inhibitory activity against aromatase [6]. 
Aromatase is a cytochrome P-450 enzyme, which is responsible for the conversion of 
androgen to estrogen in the final step of the steroid biosynthesis cascade. Inhibition of this 
enzyme is therefore of practical importance in the treatment of estrogen-dependent diseases, 
for example breast cancer, cancer of the uterine body, and endometriosis. Like aromatase, 
several other steroid organic enzymes are also cytochrome P-450 [7].  
Drugs are essential for the prevention and treatment of disease. Thus, ideal drugs are 
in great demand. But the process of Drug design is a tedious, time-consuming and cost 
intensive process. Thus, several approaches are required which collectively would form the 
basis of Computer Aided or In Silico Drug Designing. Use of computational methods in drug 
discovery and development process is nowadays gaining popularity, implementation and 
appreciation. Different terms are being applied to this area, including computer-aided drug 
design (CADD), computational drug design, computer-aided molecular design (CAMD), 
computer-aided molecular modeling (CAMM), rational drug design, In Silico drug design, 
computer-aided rational drug design. All the world’s major pharmaceutical and 
biotechnology companies use computational design tools. At their lowest level the 
contributions represent the replacement of crude mechanical models by displays of structure 
which are a much more accurate reflection of molecular reality capable of demonstrating 
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motion and solvent effects. Beyond this, theoretical calculations permit the computation of 
binding free energies and other relevant molecular properties. [8] 
 At a broader sense drug designing is classified in to two major areas, the first is 
referred to as ligand-based drug design and the second, structure-based drug design. 
Drug discovery may also require fundamental research into the biological and 
chemical nature of the diseased state. These and other aspects of drug design and discovery 
require input from specialists in many other fields and so medicinal chemists need to have 
outline knowledge of the relevant aspects of these fields.  
Drug design explain:  
1. Drug receptor interaction on the basis of various physic-chemical 
properties. 
2. Relationship between biological activity and structure.  
3. Modify the drug molecule according to the need.  
4. The effect of the drug towards the biological responds by various 
processes. [9] 
Our work is placed in the context of fundamental and original research of some 
heterocyclic compound and their derivatives, the main objective of this work is the 
application of different methods of molecular modeling to predict the chemical reactivity, 
physical property and biological activity expected in new molecules. 
The memory structure, consisting of five chapters, has been conceptually 
divided into two different parts. On the one hand, the bibliographical background section, 
which is composed by Chapter 1 and 2. On the other hand, Chapter 3, Chapter 4 and Chapter 
5 dedicated to applications and results, deepens specific practical applications.  
The contents of the chapters are briefly described: 
The first chapter the triazole and the aromatase inhibition for breast cancer 
treatment: is divided into two parts: in the first part, we will be spread out, over general 
information concerning the pharmacological classification and properties of triazole. In the 
second part, we will present general information of the breast cancer disease and therapeutic 






Chapter 2 Computational Approaches for Drug Design and Discovery: introduces 
the state of the art in molecular modeling techniques, with the special focus on the structure-
based drug discovery methods. It also gives an overview of the various algorithms and 
models that are used in in silico drug discovery with a particular spotlight on algorithms and 
scoring functions employed in this work (QSAR and docking molecular) 
The third chapter drug likeness scoring and structure activity/property 
relationships of 1,2,3-triazole derivatives as aromatase inhibitor: comprises a structural, 
electronic and energetic study on triazole and its derivatives. In this chapter we have the 
results of a comparative study on three methods used in calculation, PM3 and Density 
functional theory DFT, and Ab initio/HF, thus, the substitution effect on the electronic and 
energetic parameters of the basic core of triazole. We will also present a qualitative study on 
the relation structure-properties of a bioactive series of triazole (work published in: Journal 
of Fundamental and Applied Sciences Vol 10, No 3 (2018)). 
Chapter 4: QSAR Model for Predicting the Aromatase Inhibition Activity of 1.2.3 
triazole derivatives: In this chapter, we establish a quantitative relationship between 
physiochemical properties and biological activity of a series of bioactive derivatives of 
1,2,3- triazole (QSAR Model).  
Chapter 05: Molecular docking studies and in Silico ADMET of new substituted 
1.2.3 triazole derivatives for anti-breast cancer activity: A virtual receptor site model is 
proposed for the interaction between the triazole derivatives and the enzyme aromatase and 
Determination of PK parameters In order to identify new molecules likely to become drugs 
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THE TRIAZOLE AND THE 
AROMATASE INHIBITION FOR 
BREAST CANCER TREATMENT 
  




Breast cancer is considered to be the most common type of cancer and is the leading 
cause of cancer-related death in women accounting for an estimated 23% of new cases and 
14% of all cancer deaths in 2008 [1]. It is widely accepted that the majority of breast 
cancers are hormone-dependent and that estrogen is a key mediator in the progression and 
metastasis of breast tumors. Particularly, for postmenopausal women it has been reported 
that the concentration of 17b-estradiol (E2) in breast tumor can be tenfold higher than 
those in plasma [2]. The high concentration of E2 in breast tumors could be attributed to 
increased uptake from plasma or in situ aromatization of androgens to estrogens. The latter 
is afforded by aromatase, an enzyme involved in the rate-limiting step of estrogen 
biosynthesis by catalyzing three consecutive hydroxylation reactions that aromatize C19 
androgens to C18 estrogens. [3] 
 
Two main strategies to control or block breast cancer progression include binding of 
the estrogen receptors with estrogen receptor antagonists (such as tamoxifen), and 
inhibiting the production of estrogen with aromatase inhibitors. [4].  
Triazoles are common pharmacophore found in a diverse range of biologically active 
molecules due to their potential structural features (i.e., capability of hydrogen bonding, 
stable to metabolic degradation and less undesired effects) [5]. Based on the aromatase 
inhibitors, the triazole ring plays a pivotal role in chelation with heme iron [6]. 
 
This chapter is divided into two parts. In the first, we will talk about the triazole 
molecule (its properties, its manufacture, and its biological activity). In the second part we 
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2. THE TRIAZOLE 
2.1 Triazole ring 
[1,2,3]-Triazoles are important five-membered nitrogen heterocycles that are 
member of azole. They are aromatic ring compounds similar to the azoles, pyrazole and 
imidazole, but with an additional nitrogen atom in the ring structure. Synonyms for these 
triazoles sometimes denote that a proton is attached in the 1-position, as for example, the 
naming 1H-1,2,3-triazole or 1,2,3-1H-triazole. The table below shows the proprieties of 
this compound. [7] 
 
Table I.1 proprieties of 1.2.3 triazole 
Properties of 1, 2, 3-triazole 
 
Molecular formula C2H3N3 
Molar mass 69.0654 
Boiling point 203 °C 
Melting point 23-25 °C 
Density 1.192  
Appearance colourless liquid 
Solubility in water very soluble 
 
Generally, 1,2,3-triazoles are further subdivided into three main class, namely, 
monocyclic 1,2,3-triazoles, benzotriazoles and 1,2,3-triazolium salts as depicted in Figure 
I.1. [8] Monocyclic 1,2,3-triazoles and benzotriazoles are remarkably stable towards 
hydrolysis, oxidative/reductive conditions, and enzymatic degradation but reductive 
cleavage occurs under forcing conditions leading to the formation of triazolium salts. 
[9,10] 
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Figure I.1 classification of 1,2,3-triazole 
The features possessed by the 1, 2, 3-triazoles make them pharmaceutically 
important molecules. They are stable to reduction and oxidation as well as to hydrolysis in 
acidic and basic conditions, which indicates their high aromatic stabilization. 1,2,3-
triazoles have a high dipole moment (about 5 D) [10] and are able to participate actively in 
hydrogen bond formation as well as in dipole–dipole and π stacking interactions [11] 
which helps them in binding easily with the biological targets [12] and improves their 
solubility. 
 
2.2 . Synthetic strategies 
1,2,3-Triazole ring system has been a subject of intense research due to its versatile 
potential to interact with diverse biological systems. 
In recent years, many synthetic methodologies have been developed for the synthesis 
of this ring system. The most popular reaction to produce the 1,2,3-triazole moiety is the 
1,3-dipolar cycloaddition also known as Huisgen cycloaddition, between an azide and a 
terminal alkyne, under thermal conditions but was not initially applied much in organic 
synthesis owing to the poor regioselectivity (1,4- and 1,5-disubstituted 1,2,3-triazoles), low 
chemical yield and elevated temperatures [13]. A copper (I)- catalyzed version of azide–
alkyne cycloaddition reaction (CuAAC), the click chemistry approach invented by 
    CHAPTER I 
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Sharpless resulted in the production of a large number of 1,4-disubstituted 1,2,3- triazoles 
in very high yields [14,15]. Over the past few decades, the various synthetic methodologies 
have received a lot of attention and offered new opportunities for medicinal chemists. The 
various metal free and metal catalyzed approaches explored for the preparation of triazole 
frame work are illustrated in Figs. I.2 and I.3. [16] 
 
 
Figure I.2. A summary of various metal free approaches toward synthesis of 1,2,3-
triazoles. 
Figure. I 3. A summary of transition metal catalyzed synthesis of 1,2,3-triazoles 
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2.3 Biologically Active Derivatives 
Due to their easy access and high enzymatic stability, benzotriazole and 1,2,3-
triazole systems are frequently used as building blocks in drug design. Among antitumor 
agents, vorozole (structure 1) is a high-affinity competitive aromatase inhibitor, designed 
for inhibiting estrogen synthesis in patients with breast cancer [17-19 ]. Benzotriazole 
derivative 2 exhibits remarkable activity against leukemia, ovarian, renal, and lung cancers 
[20]. The structures may be complex, like compound 3[21], or simple, like compound 4 
[22], both of them exhibiting anti-inflammatory activities, although based on different 
principles. Nucleoside analog 5 inhibits strongly helicase activity of hepatitis C virus [23], 
whereas compound 6 and several of its analogs show strong activity against respiratory 
syncytial virus (RSV) [24]. 
Very simple derivatives of benzotriazole with biological activity include 5,6 
dimethylbenzotriazole, a very effective agent against cysts of Acanthamoeba castellanii  
[25], tetrabromobenzotriazole, which provides selective inhibition of protein kinase CK2 
[26] and induces apoptosis of Jurkat cells  [27], 1-salicylyl-4- methylbenzotriazole, 
potassium channel activator [28] and 1-isopropyl-1H-benzotriazole-4-carboxylic acid, a 
selective agonist of human orphan G-protein-coupled receptor GPR109b [29].Several 
1,2,3-triazole derivatives have been designed to target G-protein-coupled receptors. 
Among them are neurokine NK1 antagonists 7 [30,31] and 8 [32], selective A3 adenosine 
receptor agonist 9 [33] and highly selective a1 adrenoreceptor antagonists [34]. Other1,2,3-
triazole derivatives are of interest as inhibitors of some key enzymes: acetylcholinesterase 
[35], glycogen synthase kinase-3 [36], glycosidase [37], galectin-1 [38,39], and a-2,3-
sialyltransferase [40].There are also 1,2,3-triazoles with antiviral [41,42], antibacterial 
[43,44], antithrombotic [45], or antiplatelet [46] activities. Some triazoles work as 
potassium channel activators [47], others as calcium signal transduction inhibitors [48]. 
1,5- Diaryl-_2-1,2,3-triazolines are recognized anticonvulsant agents [49,50]. Among 
biologically active benzotriazoles are also inactivators of the severe acute respiratory 
syndrome 3CL protease [51], trichostatin suppressors [52], antagonists of the gonadotropin 
releasing hormone [53], and nonpeptide inhibitors of protein tyrosine phosphatase 1B [54]. 
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Figure I.4 Some Biologically active derivatives 
 
2.4 Other Applications 
Due to strong complexing affinities to copper and some other ions, benzotriazole and 
its derivatives have found wide application in anticorrosion formulations. Hundreds of 
patents covering this subject are registered each year. One of the major applications of 
such formulations is in electronics that include thiol passivation of copper interconnects 
during semiconductor manufacturing, grinding composition for polishing of semiconductor 
devices, corrosion-preventing agents for etching of insulator films in manufacture of 
semiconductor devices, cleaning solutions for electrohydrodynamic cleaning of 
semiconductors, components of polymer coatings for silver-plated circuits, and in 
dispersants for preparation of nickel-coated copper powder for electricity-conducting inks. 
Benzotriazole is also commonly used as an unticlogging agent in jet inks for forming high-
quality images. 
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Anticorrosion abilities of benzotriazole and its derivatives are also widely utilized in 
fluids for all kind of machinery. 
They are important antifriction–antiwear additives for engine oils, components of 
antirusting grease for aircraft, biodegradable lubricants for turbines, brake liquids based on 
polyoxyalkylene synthetic oils, metal corrosion inhibitors in aqueous coolants containing 
acetic acid and propylene glycol, grease for gas compressors for fuel cell systems, 
emulsifiable oil for preparation of noncombustible oil–water hydraulic emulsions for coal 
mining, environment protecting lubricating oil for refrigerators, antifreeze composition for 
diesel engines, and lubricating oil compositions for hot rolling aluminium plates. [55] 
 
3. AROMATASE INHIBITION FOR BREAST CANCER 
TREATMENT 
3.1 What Is Breast Cancer?  
Breast cancer starts when cells in the breast begin to grow out of control. These cells 
usually form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is 
malignant (cancer) if the cells can grow into (invade) surrounding tissues or spread 
(metastasize) to distant areas of the body (figureI.5). Breast cancer occurs almost entirely 
in women, but men can get breast cancer, too. Cells in nearly any part of the body can 
become cancer and can spread to other areas. [56] 
 
Figure I-5 Anatomy of the Female Breast. 
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3.2 Breast cancer molecular subtypes 
In breast cancer, hormone receptors are the proteins located in and around breast 
cells. These receptors signal cells — both healthy and cancerous — to grow. In the case of 
breast cancer, the hormone receptors tell the cancer cells to grow uncontrollably, and a 
tumor result. Hormone receptors can interact with estrogen or progesterone. Estrogen 
receptors are the most common. This is why ER-positive is the most common form of 
breast cancer.[57] 
Profiling the biologic make-up of breast cancer tissue can help doctors determine 
how well a patient will respond to different cancer treatments and how aggressive the 
cancer might be. Researchers are focused on three subtypes—hormone receptor-positive, 
HER2-positive, and triple-negative breast cancer 
 
Figure 3-6 Breast cancer molecular subtypes 
 
3.2.1 Hormone Receptor-Positive Breast Cancer 
About 80% of all breast cancers are “ER-positive.” (figure I.6) That means 
the cancer cells grow in response to the hormone estrogen. About 65% of these are also 
“PR-positive.” They grow in response to another hormone, progesterone. 
If your breast cancer has a significant number of receptors for either estrogen or 
progesterone, it’s considered hormone-receptor positive. 
Tumors that are ER/PR-positive are much more likely to respond to hormone therapy 
than tumors that are ER/PR-negative. 
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You may have hormone therapy after surgery, chemotherapy, and radiation are 
finished. These treatments can help prevent a return of the disease by blocking the effects 
of estrogen. They do this in one of several ways. 
 
Figure 3.7 ER+ breast cancer cell 
 
3.2.2 HER2-Positive Breast Cancer 
In about 20% of breast cancers, the cells make too much of a protein known as 
HER2. These cancers tend to be aggressive and fast-growing. 
For women with HER2-positive breast cancers, the drug trastuzumab (Herceptin) has 
been shown to dramatically reduce the risk of the cancer coming back. It‘s standard 
treatment to give this medication along with chemotherapy after surgery to people 
with breast cancer that’s spread to other areas. It can also be used for early-stage breast 
cancer. But there is a small but real risk of heart damage and possible lung damage. 
Scientists are still studying how long women should take this medication for the greatest 
benefit. 
 
3.2.3 Triple-Negative Breast Cancer 
Some breast cancers (between 10% and 20%) are known as “triple negative” because 
they don’t have estrogen and progesterone receptors and don’t overexpress the HER2 
protein. Many breast cancers associated with the gene BRCA1 are triple negative. [58] 
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3.3 Treatment options 
 
If breast cancer is not treated, the cancer cells in the breast will keep growing. They 
can spread to other parts of the body, such as bones, the liver or the lungs. This is called 
secondary breast cancer. Over time, these cancer cells can stop some organs in your body 
from working, or lead to other life-threatening problems.  
Breast cancer is treated in several ways. It depends on the kind of breast cancer and 
how far it has spread. People with breast cancer often get more than one kind of treatment. 
[59]  
The Table I.2 summarizes these types. 
Table I.2 treatment options 
 
3.3.1 Hormone therapy for breast cancer 
 Hormone therapy to treat breast cancer uses drugs or treatments to lower levels or 
block the action of female sex hormones (estrogen and progesterone) in a woman's body. 
This helps slow the growth of many breast cancers. 
Hormone therapy makes cancer less likely to return after breast cancer surgery. It 
also slows the growth of breast cancer that has spread to other parts of the body. 
Hormone therapy can also be used to help prevent cancer in women at high risk for 
breast cancer.  
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Figure 3-8 Estrogen hormone level 
Hormone therapy can work in two ways: 
 By blocking the estrogen from acting on cancer cells 
 By lowering estrogen levels in a woman's body [62]. 
3.3.2 Drugs That Block Estrogen 
Some drugs work by blocking estrogen from causing cancer cells to grow. [62]. 
 Tamoxifen (Nolvadex)  
 Toremifene (Fareston) 
 Fulvestrant (Faslodex) 
3.3.3 Drugs That Lower Estrogen Levels 
Some drugs, called aromatase inhibitors (AIs), stop the body from making estrogen 
in tissues such as fat and skin. But these drugs do not work to make the ovaries stop 
making estrogen. For this reason, they are used mainly to lower estrogen levels in women 
who have been through menopause (postmenopausal). Their ovaries no longer make 
estrogen. 
 
Premenopausal women can take AIs if they are also taking drugs that stop their 
ovaries from making estrogen. [60] 
Aromatase inhibitors include: 
 Anastrozole (Arimidex) 
 Letrozole (Femara) 
 Exemestane (Aromasin)  
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3.4  What is an aromatase inhibitor and how does it work? 
Aromatase (CYP19) is an enzyme of the cytochrome P450 superfamily that catalyzes 
the final and rate-limiting step of the conversion of androgens, testosterone and 
androstenedione, into estrogens, estradiol and estrone, respectively. 
Aromatase inhibitors and inactivators interfere with the body’s ability to produce 
estrogen from androgens by suppressing aromatase enzyme activity Before menopause, 
ovarian aromatase is responsible for the majority of circulating estrogen and is exquisitely 
sensitive to changes in luteinising hormone (LH). Following menopause, aromatase in fat 
and muscle may be responsible for much of the circulating estrogen. Aromatase in highly 
estrogen-sensitive tissues, such as the breast, uterus, vagina, bone, brain, heart and blood 
vessels, provides local estrogen in an autocrine fashion. [61] . 
 
3.5 The overall structure of aromatase 
A ribbon diagram of the overall crystal structure of human placental aromatase is 
shown in Figure. I.4 The tertiary structure consists of 12 major helices (labeled A through 
L) and 10 strands (numbered 1 through 10) distributed into 1 major and 3 minor sheets, 
and follows the characteristic cytochrome P450 fold. The bound androstenedione molecule 
at the heme distal site, the active site of the enzyme, and shown within its unbiased 
electron density, makes two hydrogen bond-forming contacts the 3-keto and 17- keto 
oxygens with Asp309 side chain and Met374 backbone amide, respectively (Figure.I.9). 
The major _-sheet is a mixed 4-stranded sheet that begins near the amino terminus (first 
two strands are 1:83–88 and 2:93–97) but ends in two strands from the carboxyl terminal 
half of the polypeptide chain (3:373–376 and 6:393–396).  
A feature somewhat special to the aromatase structure is that the amino-terminal 
residues 47–50, which makes one backbone hydrogen bond with _1, adds an extra _-
strand-like element to this sheet. Each of the three minor sheets consists of two anti-
parallel strands scattered over the polypeptide chain (sheet2: 4:381–383 and 5:386–388; 
sheet3: 8:473–475 and 9:479–481; sheet 4: 7:458–461 and 10:491–494). Of the 12 major 
helices, the lengths, locations and orientations of helices I (293–324), F (210–227), G 
(242–267), H (278–287), C (138–152), D (155–174), E (187–205), J (326–341), K (354–
366) and L (440–455) are similar to those found in most of the cytochrome P450s. Other 
helices, namely A(57–68), A (69–80), B (100–109), B(119–126), G(232–236), H(271–
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274), J(346–349), K(398–404), and K (414–418) are 1–4 turns long and have more 
variability among P450s in terms of their locations, lengths and orientations. Forinstance, 
when compared with two human P450s 3A4 and 2D6 that aromatase has the closest 
resemblance to (∼14–18% sequence identity), the helix Ain aromatase is longer than a 
similar one in 3A4 and is not seen in 2D6. The other notable difference in the secondary 
structures between aromatase and 3A4 is that the helix F in 3A4 is separated into two 
shorter helices by a stretch of polypeptide. 
As discussed below, this region of the structure contributes significantly to the 
constitution of the active site. Another difference is that the G-helix in aromatase is at least 
1 turn longer than those in 3A4 and 2D6. The F-helix–loop–G-helix region, in general, 
appears to be different in different P450s. With the helix G_ in the middle, the loop is 




Figure. I.9 A ribbon diagram showing the overall structure of human placental aromatase. 
 
A striking feature of the tertiary aromatase structure is that long loops interconnect 
well-defined secondary structure elements, in general agreement with other P450 
structures. One example is the polypeptide between the 2-turn helix Kand helix L. This 
stretch of 35 residue polypeptides (405–439), devoid of much secondary structure except 
the 1-turn helix K, contributes the all-important cysteine ligand (Cys437) to the heme iron. 
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Other examples of long loops are between helices Band C, 7 and 8, and 9 and 10, all of 
which either contribute active site residues or have roles in the scaffolding of functionally 
important elements. Although these loops have little intra-loop interactions through 
hydrogen bonding, they stabilize by interacting with other structural elements and are, 
thus, well-defined in the electron density map. Another feature common to all cytochrome 
P450s is the ligation of the heme group via its propionate moieties by arginine and 
tryptophan side chains through ionic and hydrogen bonding interactions. These side 
residues in aromatase are Arg115, Trp141, Arg145, Arg375, and Arg435, homologous to 
those in 3A4, 2D6 and others.  [63] 
 
3.6 Types of aromatase inhibitors  
AIs are classified as first, second, or third generation according to the specificity and 
potency with which they inhibit the aromatase enzyme. They are further subclassified as 
type 1 or type 2 inhibitors, according to the reversibility of their inhibitory activity (Table 
I.5). 
 
Type 1 inhibitors, steroidal analogues of androstenedione, irreversibly inhibit the 
aromatase enzyme by covalently binding to it, thus earning the name “suicidal inhibitors.” 
Permanent inactivation persists after discontinuation of the drug until the peripheral tissues 
synthesize new enzymes.  
In contrast, nonsteroidal type 2 inhibitors bind reversibly to the aromatase enzyme, 
resulting in competitive inhibition [64]. Third-generation AIs (i.e., anastrozole, letrozole, 
and exemestane) are the most potent, most selective, and least toxic AIs known today and 
can reduce serum estrogen by more than 95%. In addition, their pharmacokinetic properties 
(a half-life of approximately 48 hours for anastrozole and letrozole and 27 hours for 
exemestane) allow for a once-daily dosing schedule [65].  
Their selective inhibitory properties allow their use without the need for 
supplemental corticosteroidal or mineralocorticoid supplementation, as is the case with the 
nonspecific AI aminoglutethimide. 
Several clinical trials have evaluated the efficacy and safety of these agents. Here, we 
review the published literature regarding these trials and summarize advances in the 
hormonal treatment of breast cancer. 
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3.7  Mechanisms of action 
The AIs are classified into two types: (a) type I, suicidal or noncompetitive inhibitors; and 
(b) type II, competitive inhibitors [66,67]. Type I inhibitors are steroidal compounds, and 
type II inhibitors are nonsteroidal drugs. Both types mimic normal substrates (androgens), 
competing with the substrate for access to the binding site on the enzyme. After initial 
binding, the next step differs for the two types: once a noncompetitive inhibitor has bound, 
the enzyme initiates its typical sequence of hydroxylation, but hydroxylation produces an 
unbreakable covalent bond between the inhibitor and the enzyme protein. Enzyme activity 
is thus permanently blocked; even if all unattached inhibitor is removed, enzyme activity 
can only be restored by new enzyme synthesis. Competitive inhibitors reversibly bind to 
the active enzyme site, and either no enzyme activity is triggered, or it is without effect. 
The inhibitor can disassociate from the binding site, allowing renewed competition 
between the inhibitor and the substrate for binding to the site. As a result, the effectiveness 
of competitive inhibitors depends on the relative concentrations and affinities of the 
inhibitor and the substrate. Continued activity requires constant presence of inhibitor. 
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To compete for binding to the active site, both competitive and noncompetitive inhibitors 
must necessarily share important structural features with the endogenous substrate. 
Noncompetitive inhibitors must also share structural features with androgens, allowing 
them to interact with the catalytic residual on the enzyme protein. This renders them 
inherently selective. By contrast, most competitive inhibitors interact with the heme iron, a 
common feature of all cytochrome P450 enzymes. Some may also bind to the highly 
conserved oxygen binding site in addition to the substrate binding site. Thus, unless the 
specificity of a competitive inhibitor is reinforced through other structural features, it may 
block the activity of a variety of cytochrome P450 enzymes, as does aminoglutethimide. 
Both anastrozole and letrozole are type II nonsteroidal AIs, whereas exemestane has a 
steroidal structure and is classified as a type I AI, also known as an aromatase inactivator 
because it irreversibly binds with and permanently inactivates the enzyme. The clinical 




Figure I.9 Mechanism of Action of Aromatase Inhibitors 
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1. INTRODUCTION  
Drug design is an integrated developing discipline which portends an era of tailored 
drug. It involves study of effects of biologically active compounds on the basis of molecular 
interactions in terms of molecular structure or its physicochemical properties involved. Its 
studies processes by which the drugs produce their effects, how they react with the 
protoplasm to elicit a particular pharmacological effect or response, how they are modified 
or detoxified, metabolized or eliminated by the organism. Currently two major molecular 
modeling strategies are employed in drug design process, ligand-based drug design and 
structure-based drug design. Drug discovery is constantly reevaluating itself in order to 
advance in speed, efficiency, and quality and thus remain successful. [1] 
Studies of drug databases showed that successful drugs tend to have ‘drug-like 
properties. Drug likeness, when viewed at the in vivo level, is thought of in terms of PK and 
safety. These complex in vivo properties result from an interaction of physicochemical and 
structural properties, such as solubility, permeability and stability, which are studied in vitro. 
These properties are, in turn, dictated by fundamental molecular properties, such as 
molecular weight, hydrogen bonding and polarity, which are studied in silico. [2] 
 
2. COMPUTER-AIDED DRUG DESIGN BASIC PRINCIPLES 
CADD refers to the application of informatics to the discovery, design and 
optimization of biologically active compounds. Some of the most commonly used 
techniques will be described shortly. 
2.1. Quantum Mechanics and Molecular Mechanics 
There are two different approaches to compute the energy of a molecule. First, 
quantum mechanics, a procedure based on first principles. In this approach, nuclei are 
arranged in the space and the corresponding electrons are spread all over the system in a 
Continuous electronic density and computed by solving the Schrödinger equation. When 
chemical reactions do not need to be simulated, classical mechanics can describe the 
behavior of a Bimolecular system. This mathematical model is known as molecular 
mechanics, and can be used to compute the energy of systems containing a large number of 




In contrast to quantum mechanics, molecular mechanics ignore electrons and compute 
the energy of a system only as a function of the nuclear positions. Then, it is possible to take 
into account nan implicit way the electronic component of the system by adequate 
parameterization of the potential energy function. The set of equations and parameters which 
define the potential surface of a molecule is called force field. [3] 
2.2. Force Fields 
In molecular mechanics the electrons and nuclei of the atoms are not explicitly 
included in the calculations. Molecular mechanics considers a molecule to be a collection of 
masses interacting with each other through harmonic forces. Thus, the atoms in molecules 
are treated as ball of different sizes and flavors joined together by springs of variable strength 
and equilibrium distances (bonds). This simplification allows using molecular mechanics as 
a fast-computational model that can be applied to molecules of any size. 
In the course of a calculation the total energy is minimized with respect to the atomic 
coordinates, and it consists of a sum of different contributions that compute the deviations 
from equilibrium of bond lengths, angles, torsions and non-bonded interactions:  
 
Where:  
Etot is the total energy of the molecule,  
Estris the bond-stretching energy term,  
Ebend is the angle-bending energy term,  
Etors is the torsional energy term,  
Evdw is the van der Waals energy term,  
Eelec is the electrostatic energy term. 
The equilibrium values of bond lengths and bond angles are the corresponding force 
constants used in the potential energy function in the force field and it defines a set known 





Each deviation from these equilibrium values will result in increasing total energy of 
the molecule. So, the total energy is a measure of intramolecular strain relative to a 
hypothetical molecule with an ideal geometry of equilibrium. By itself the total energy has 
no strict physical meaning, but differences in total energy between two different 
conformations of the same molecule can be compared. [4,5] 
2.3. Molecular dynamics 
Molecular dynamics (MD) is a computational technique in which successive 
configurations of a system are generated by integrating the Newton’s law of motion. The 
result is a trajectory that describes how the positions and velocities of particles in the system 
vary with time [ 6] MD simulations of biological macromolecules provide atomic detail on 
the internal motions of 
these systems. Constant improvements in the methodology and computational power, 
extended the use of molecular dynamics studies to larger systems including, for example, 
explicit solvent and/or membrane environment, greater conformational changes and longer 
time scales. [7] 
Drug design applications of molecular dynamics simulations include the estimation of 
free energies of binding, prediction of target selectivity, generation of multiple 
conformations for flexible docking, development of dynamic protein-based 
pharmacophores, metabolism prediction and refinement of protein homology models. [8] 
2.4.  Energy-Minimizing Procedures  
 
Energy minimization methods can be divided into different classes depending on the 
order of the derivative used for locating a minimum on the energy surface. Zero order 
methods are those that only use the energy function to identify the regions of low energy 
through a grid search procedure. The most well-known method of this kind is the SIMPLEX 
method. Within first-derivative techniques, there are several procedures like the steepest 
descent method or the conjugate gradient method that make use of the gradient of the 
function. Second-derivative methods, like the Newton-Raphson algorithm make use of the 





2.4.1. Steepest Descent Method  
In the steepest descent method, the minimizer computes numerically the first 
derivative of the energy function to find a minimum. The energy is calculated for the initial 
geometry and then again after one of the atoms has been moved in a small increment in one 
of the directions of the coordinate system. This process is repeated for all atoms which finally 
are moved to a new position downhill on the energy surface. The procedure stops when a 
predetermined threshold condition is fulfilled. The optimization process is slow near the 
minimum, and consequently, the steepest descent method is often used for structures far 
from the minimum as a first, rough and introductory run followed by a subsequent 
minimization employing a more advanced algorithm like the conjugate gradient.  
2.4.2. Conjugate Gradient Method  
The conjugate gradient algorithm accumulates the information about the function from 
one iteration to the next. With this proceeding the reverse of the progress made in an earlier 
iteration can be avoided. For each minimization step the gradient is calculated and used as 
additional information for computing the new direction vector of the minimization 
procedure. Thus, each successive step refines the direction towards the minimum. The 
computational effort and the storage requirements are greater than for steepest descent, but 
conjugate gradients are the method of choice for larger systems. The greater total 
computational expense and the longer time per iteration is more than compensated by more 
efficient convergence to the minimum achieved by conjugate gradients. [11] As a summary, 
the choice of the minimization method depends on two factors: the size of the system and 
the current state of the optimization. For structures far from minimum, as a general rule, the 
steepest descent method is often the best minimizer to use for 100-1000 iterations. The 
minimization can be completed to convergence with conjugate gradients.  There are several 
ways in molecular minimization to define convergence criteria. In non-gradient minimizers 
only, the increments in the energy and the coordinates can be taken to judge the quality of 
the actual geometry of the molecular system. In all gradient minimizers, however, atomic 
gradients are used for this purpose. The best procedure in this respect is to calculate the root 
mean square gradients of the forces on each atom of a molecule. The value chosen as a 
maximum derivative will depend on the objective of the minimization. If a simple relaxation 
of a strained molecule is desired, rough convergence criterions like a maximum derivative 
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of 0.1 kcal mol-1Å-1 is sufficient while for other cases convergence to a maximum 
derivative less than 0.001 kcal mol-1Å-1 is required to find a final minimum. [12] 
 
3. DRUG-LIKE PROPERTIES 
 
Since 2001, when the “property-based design” concept was presented by van 
deWaterbeemd et al., [13] there has been an increased focus on its application in drug design 
and discovery [14–15]. 
The relationship between chemical structure and physicochemical properties has 
attracted the attention of medicinal chemists as a new drug research and development 
strategy that complements the structure-activity relationships in the progress of drug design 
and discovery. 
The chemical structure of a drug influences its physicochemical properties, and the 
physicochemical properties of a drug molecule [16], such as MW, lipophilicity, aqueous 
solubility (S), permeability, acid-base ionization constant (pKa), HBD and HBA, ROT and 
PSA, can be changed by modifying its structure. Further, these physicochemical properties 
of drug molecule influence its ADME/Tox properties (drug-like properties), such as 
metabolic stability, plasma stability, P-glycoprotein (Pgp) extrusion, serum albumin binding, 
cytochrome P450 (CyP450) inhibition, human Ether-à-go-go-Related Gene (hERG) 
inhibition, the ability to across the blood brain barrier (BBB), pharmacokinetics (PK) and 
toxicity. Ultimately, these physicochemical properties and the ADME/Tox properties of a 
drug molecule affect its pharmacodynamics activity. [17] 
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The fastest method for evaluating the drug-like properties of a compound is to apply 
“rules.” 
Rules are a set of guidelines for the structural properties of compounds that have a 
higher probability of being well absorbed after oral dosing. The values for the properties 
associated with rules are quickly counted from examination of the structure or calculated 
using software that is widely available. 
4.1 Lipinski Rules (Oral drug properties) 
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule of five 
(RO5) is a rule of thumb to evaluate drug likeness or determine if a chemical compound with 
a certain pharmacological or biological activity has properties that would make it a likely 
orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997. 
[18] 
The impact of these rules in the field has been very high. This acceptance can be 
attributed to many factors: [17] 
 The rules are easy, fast, and have no cost to use. 
 The “5” mnemonic makes the rules easy to remember. 
 The rules are intuitively evident to medicinal chemists. 
 The rules are a widely used standard benchmark. 
 The rules are based on solid research, documentation, and rationale. 
 The rules work effectively. 
Lipinski's rule states that, in general, an orally active drug has no more than one 
violation of the following criteria: 
1. Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or 
more hydrogen atoms). 
2. Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms). 
3. A molecular mass less than 500 daltons. 
4. An octanol-water partition coefficient log P not greater than 5. 




4.2 Veber Rules 
Additional rules were proposed by Veber et al. They studied structural properties that 
increase oral bioavailability in rats. They concluded that molecular flexibility, polar surface 
area (PSA), and hydrogen bond count are important determinants of oral bioavailability. 
Rotatable bonds can be counted manually or using software. PSA is calculated using 
software and is closely related to hydrogen bonding. [20] 
Veber rules for good oral bioavailability in rats are as follows: 
 ≤10 rotatable bonds 
 ≤140 Å2 PSA, or≤12 total hydrogen bonds (acceptors plus donors) 
 
5. STRATEGIES OF IN SILICO DESIGN 
 
In silico drug design can be applied by either of two strategies of design depending on 
the knowledge of the target, presence of the primary sequence and 3D structure. These two 
strategies are: 
5.1 Ligand-based drug design  
In the absence of the receptor 3D information, lead identification and optimization 
depend on available pharmacologically relevant agents and their bioactivities. The 
computational approaches include QSAR, pharmacophore modeling, and database mining, 
[21] In this work, we will use QSAR. 
  
5.1.1 Quantitative structure-activity Relationship 
 Is the process by which chemical structure is quantitatively correlated with a well-
defined process, such as biological activity or chemical reactivity.  For example, biological 
activity can be expressed quantitatively as in the concentration of a substance required to 
give a certain biological response. Additionally, when physicochemical properties or 
structures are expressed by numbers, one can form a mathematical relationship, or 





The mathematical expression can then be used to predict the biological response of 
other chemical structures. QSAR's most general mathematical form is  
Activity = f (physiochemical properties and/or structural properties) 
That the three key components required for the development of a QSAR model are: 
 Some measure of the activity for a group of chemicals in a biological or 
environmental system – toxicological endpoint. 
 A description of the physicochemical properties and/or structure for this 
group of chemicals. 
 Molecular descriptors. 
 A form of statistical relationship to link activity and descriptors [22] 
5.1.2 The data to model 
The modeler, and user of a model, must consider the data to model. Data should, 
ideally, be of high quality, meaning they are reliable and consistent across the data set to be 
modelled. The definition of data quality is, at best, subjective and is likely to be different for 
any effect, endpoint or property. 
Therefore, the modeler or user should determine whether the data are performed in a 
standard manner, to a recognized protocol, and if they are taken from single or multiple 
laboratories. [23] 
5.1.3 Molecular Descriptors 
Despite great advances in the field of drug design, the use of descriptors to define the 
molecular structure of biologically active compounds is the main method utilized to discover 
new lead molecules. Descriptors are the chemical characteristic of a molecule in numerical 





Figure II.1 Molecular Descriptors 
 
5.1.4 Statistical methods used in QSAR analysis 
Statistical methods are an essential component of QSAR work. They help to build 
models, estimate a model's predictive abilities, and find relationships and correlations among 
variables and activities. A suitable statistical method coupled with a variable selection 
method allows analysis of this data in order to establish a QSAR model with the subset of 
descriptors that are most statistically significant in determining the biological activity. The 
statistical method can be broadly divided in to two: linear and non-linear method. In statistics 
a correlation is established between dependent variables (biological activity) and 
independent variables (physiochemical properties or molecular descriptor). The liner method 
fits a line between the selected descriptor and activity as compared to non-linear method 
which fit a curved between the selected descriptor and activity. The statistical method to 
build QSAR model is decided based on the type of biological activity data. Following are 





In our study we used the MLR method. 
 Multiple Linear Regression (MLR)  
can be considered as an easy interpretable regression-based method, regression 
analysis correlates independent X variables or descriptors with dependent Y variables 
(biological data). The regression model assumes a linear relationship between m molecular 
descriptors and the response (biological activity) variable.  
This relationship can be expressed with the single multiple-term linear equation: 
 
Y = b0 + b1X1 + b2X2 + …. + bmXm+e 
 
The MLR analysis calculates the regression coefficients, bi, by minimizing the 
residuals, which quantify the deviations between the data (Y) and the model (Y'), as in the 
case of simple linear regression. [26] 
 
5.1.5 Validation of the QSAR model  
QSAR studies aimed to derive a model that is optimally active, means the model 
should provide a reliable estimate of the activity of new or untested compound similar to 
those in it. After development of the model it is necessary to test whether any data from the 
data set affect model extensively. This is done by using QSAR validation methods. 
Validation method is required to ensure model reliability, to ensure that the model is not due 
to chance factor. Various types of validation methods are used in the QSAR studies to predict 
1. Principal component analysis (PCA) 
2. Cluster analysis 
3. Simple liner regression  
4. Multiple liner regression  
5. Stepwise multiple liner regression  
6. Principle component regression (PCR)  
7. Continuum Regression  
8. Partial least squares (PLS)  
 
9. Genetic function approximation (GFA)  
10. Genetic partial least squares (GPLS)  
11. Logistic regression  
12. K-Nearest Neighbor classification 
(KNN)  
13. Neural Network  
14. Discriminant analysis  
15. Decision Trees  




the accuracy of model or to estimate the validity or predictivity of the derived structure 
property model. [25] 
  
 Internal validation parameters 
Internal validation uses the dataset from which the model is built and checks for 
internal stability. Cross-Validation (CV) technique is widely employed as an internal 
validation method of statistical models (23-26). Usually, one compound of the set is 
extracted each time, and then the model is recalculated using as training set the n-1 (where 
n is number of compounds) remaining compounds, so that the biological activity value for 
the extracted compound is predicted once for all compounds. This process is repeated n times 
for all the compounds of the initial set, thus obtaining a prediction for each object. This 
process referred as leave-one-out (LOO) method. [25] 
This validation is done using the data that created the model. The various internal 
validation parameters invoked in this study are presented thus; 
 
Table 5-2 Statistical parameters for cross-validation 
Statistic 
Definition Formula 
𝑹𝒄𝒗𝟐  the square of the correlation coefficient [27] 𝑅𝐶𝑉2 = 1 − ∑(𝑦𝑖 − ?̂?𝑖 )
2∑(𝑦𝑖 − 𝑦𝑖 ̅ ) = 1 − 𝑃𝑅𝐸𝑆𝑆𝑆𝑆𝑌  𝑌𝑖 the experimental property ?̂?𝑖; the predicted property ?̅?𝑖the mean experimental 𝑹𝒂𝒅𝒋𝟐  the square of the correlation coefficient Adjusted [18] p = number of independent variables in the model 
 
F Variance Ratio [29] 
 
S Standard error of estimate [29] 𝑆 = ∑(𝑦𝑖 − ?̂?𝑖)2𝑛 − 𝑝 − 1  
SSY Total Sum of Squares (TSS) [30] 𝑠𝑠𝑦 =∑(𝑦𝑖 − 𝑦𝑖 ̅ ) 
(PRESS) Predictive Error Sum of Squares [30] 𝑝𝑟𝑒𝑠𝑠 =∑(𝑦𝑖 − ?̂?𝑖 )2 
 
𝐹 = ∑(?̂?𝑖 − ?̅?𝑖)2𝑝 ∑(𝑦𝑖 − ?̂?𝑖)2𝑛 − 𝑝 − 1  
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 External validation  
Several authors have suggested that the only way to estimate the true predictive power 
of a QSAR model is to compare the predicted and observed activities of an (sufficiently 
large) external test set of compounds that were not used in the model development. 
To estimate the predictive power of a QSAR model, Golbraikh and Tropsha 
recommended use of the following statistical characteristics of the test set [31,32]: 
 
Table II.3 Statistical parameters for external validation 
Statistic      Definition Formula 𝑹𝒑𝒓𝒆𝒅 𝐄𝐗𝐓𝟐  Predictive residual sum of squares(external validation) [33] 
 
𝑅𝑝𝑟𝑒𝑑2 = 1 − ∑(𝑦𝑖 − ?̂?𝑖 )2  ∑(𝑦𝑖 − 𝑦𝑖 ̅ )  
Golbraikh and Tropsha’s criteria 𝑹°𝟐 The squared correlation coefficient predicted versus 
observed [20] 
𝑅°2 = 1 − ∑ (?̂?𝑖 − 𝑦𝑖𝑟°)2𝑛𝑡𝑒𝑠𝑡𝑖=1∑ (?̂?𝑖 − ?̅̂?)2𝑛𝑡𝑒𝑠𝑡𝑖=1 , 𝑦𝑖𝑟° = 𝐾?̂?𝑖  𝑹′°𝟐 The squared correlation coefficient 
versus predicted activities 
𝑅′°2 = 1 − ∑ (𝑦𝑖 −?̂?𝑖𝑟°)2𝑛𝑡𝑒𝑠𝑡𝑖=1∑ (𝑦𝑖 −?̅?)2𝑛𝑡𝑒𝑠𝑡𝑖=1 , ?̂?𝑖𝑟° = 𝐾′𝑦𝑖       
K The slopes of regression 𝐾 = ∑ 𝑦𝑖 𝑛𝑡𝑒𝑠𝑡𝑖=1 ?̂?𝑖∑ ?̂?𝑖2𝑛𝑡𝑒𝑠𝑡𝑖=1  
K' The slopes of regression 𝐾′ = ∑ 𝑦𝑖 𝑛𝑡𝑒𝑠𝑡𝑖=1 𝑦?̂?∑ 𝑦𝑖2𝑛𝑡𝑒𝑠𝑡𝑖=1  
Matrice for external validation 𝒓𝒎𝟐  
Closeness between the R2 and 
R20 
determination coefficients 
𝑟𝑚2 = 𝑅2 (1 − √|𝑅2 − 𝑅°2|) 𝒓𝒎′𝟐 𝑟𝑚′2 = 𝑅2 (1 − √|𝑅2 − 𝑅′°2|)  𝒓𝒎(𝒕𝒆𝒔𝒕)𝟐̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅  𝑟𝑚(𝑡𝑒𝑠𝑡)2̅̅ ̅̅ ̅̅ ̅̅ ̅̅ = 𝑟𝑚2 + 𝑟𝑚′22  












5.1.6 Evaluation of the model 
A developed QSAR model can be accepted generally in QSAR studies when it can 
satisfy the following criterion : 
 If correlation coefficient R ≥ 0.8 (for in vivo data). 
 If coefficient of determination R2 ≥ 0.6 
 If the standard deviation s is not much larger than standard deviation of the 
biological data. 
 If its F value indicate that overall significance level is better than 95%. 
 If its confidence interval of all individual regression coefficients proves that 
they are justified at the 95% significance level. 
 If cross-validated R2 (Q2) > 0.5 
 If R2 for external test set, R2 pred > 0.6 
  (r2 – r20) /r2 < 0.1 and 0.85 ≤ K ≤ 1.15, or (r2 –r'20) / r2 < 0.1 and 
0.85 ≤ K' ≤ 1.15 (for test set). 
 r2 m (overall) and R2p are ≥ 0.5 (or at least near 0.5). 
 External validation parameters for a predictive model, have to satisfy a 
threshold value which is 0.85 for CCC. [35] 
 
Equation has to be rejected 
 If the above-mentioned statistical measures are not satisfied. 
 If the number of the variables in the regression equation is unreasonably large. 
 If standard deviation is smaller than error in the biological data. [36] 
 
5.2 STRUCTURE-BASED DRUG DESIGN STRATEGIES SBDD 
Structure-based design has played an important role in drug discovery and 
development. This approach requires the understanding of receptor–ligand interactions. If 
the target 3D structure is known, it can be used for the design of new ligands.   





5.2.1 Definition of Molecular docking  
Molecular docking studies are used to determine the interaction of two molecules and 
to find the best orientation of ligand which would form a complex with overall minimum 
energy. The small molecule, known as ligand usually fits within protein’s cavity which is 
predicted by the search algorithm. This protein cavity becomes active when comes in contact 
with any external compounds and are thus called as active sites. 
The results are analyzed by a statistical scoring function which converts interacting 
energy into numerical values called as the docking score; and also, the interacting energy is 
calculated. The 3D pose of the bound ligand can be visualized using different visualizing 
tools like Pymol, Rasmol etc which could help in inference of the best fit of ligand. 
Predicting the mode of protein-ligand interaction can assume the active site of the protein 
molecule and further help in protein annotation. [36] 
 
Figure II.2 Molecular docking flow chart 
 
5.2.2 Different types of interactions 
Interactions between particles can be defined as a consequence of forces between the 
molecules contained by the particles. These forces are divided into four categories: 
 Electrostatic forces - Forces with electrostatic origin due to the charges 
residing in the matter. The most common interactions are charge-charge, 
charge-dipole and dipole-dipole. 
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 Electrodynamics forces-The most widely known is the Van der Waals 
interactions. 
 Steric forces - Steric forces are generated when atoms in different molecules 
come into very close contact with one another and start affecting the 
reactivity of each other. The resulting forces can affect chemical reactions 
and the free energy of a system. 
 Solvent-related forces - These are forces generated due to chemical 
reactions between the solvent and the protein or ligand. Examples are 
Hydrogen bonds (hydrophilic interactions) and hydrophobic interactions. 
A common characteristic of all these forces is their electromagnetic nature. 
Other physical factors - Conformational changes in the protein and the ligand 
are often necessary for successful docking. [37] 
5.2.3 Types of docking  
The following are majorly used type of docking are: 
 Lock and Key or Rigid Docking: In rigid docking, both the internal 
geometry of the receptor and ligand is kept fixed during docking. 
 Induced fit or Flexible Docking:  In this model, the ligand is kept flexible 
and the energy for different conformations of the ligand fitting into the 
protein is calculated. Though more time consuming, this method can evaluate 
many different possible conformations which make it more reliable.[38]  
 
5.2.4  Mechanics of docking  
To perform a docking screen, the first requirement is a structure of the protein of 
interest usually the structure has been determined using a biophysical technique such as x-
ray crystallography, or less often, NMR spectroscopy. This protein structure and a database 
of potential ligands serve as inputs to a docking program. The success of a docking program 
depends on two components: the search algorithm and the scoring function. [39] 
Search algorithm: These algorithms determine all possible optimal conformations for 
a given complex (protein-protein, protein-ligand) in an environment i.e. the position and 
orientation of both molecules relative to each other. They can also calculate the energy of 
the resulting complex and of each individual interaction. [40] 
The different types of algorithms that can be used for docking analysis are: 
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 Molecular dynamics 
 Monte Carlo methods 
 Genetic algorithms 
 Fragment-based methods 
 
 Point complementary 
methods 
 Distance geometry methods 
 Systematic searches 
 
 
Scoring function: These are mathematical methods used to predict the strength of the 
noncovalent interaction called as binding affinity, between two molecules after they have 
been docked. Scoring functions have also been developed to predict the strength of other 
types of intermolecular interactions, for example between two proteins or between protein 
and DNA or protein and drug. These configurations are evaluated using scoring functions to 
distinguish the experimental binding modes from all other modes explored through the 
searching algorithm. [41] 
For example: 
• Empirical scoring function of Igemdock       Fitness = vdW + Hbond + Elec 
• Binding Energy   ΔG bind = ΔGvdw + ΔGhbond + ΔGelect + ΔGconform + ΔG tor + ΔG sol  
5.2.5 Major steps involved in mechanics of molecular docking 
Molecular Docking is the process in which the intermolecular interaction between two 
molecules was studied in In-silico. In this process, the Macromolecule is the protein receptor. 
The micro molecule is the Ligand molecule which can be acted as an inhibitor. So, the 
Docking process involves the following steps: 
Step I – preparation of protein:  
Three-dimensional structure of the Protein should be retrieved from Protein data bank 
(PDB); afterward the retrieved structure should be pre-processed. This should admit removal 
of the water molecules from the cavity, stabilizing the charges, filling the missing residues, 





Step II – active site prediction:  
After the preparation of protein, the active site of protein should be predicted. The 
receptor might possess lots of active sites merely the one of the concerns should be picked 
out. Mostly the water molecules and hetero atoms are removed if present. 
Step III – preparation of ligand: 
Ligands can be retrieved from several databases such as ZINC, Pub Chem or can be 
sketched applying Chem sketch tool. 
Step IV- docking:  
Ligand is docked against the protein and the interactions are analyzed. The scoring 
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The 1,2,3- triazole can be divided in three subclasses depending on the position of 
the substituants in the ring. While 1H-1,2,3-triazole and 2H-1,2,3-triazole are aromatic 
compounds but their 4H-1,2,3-triazole isomers are not. This fact reflects the abundance of 
1H- and 2H-1,2,3-triazoles and the scarcity of 4H-1,2,3-triazoles [1]. 
The two tautomeric forms: 1H- and 2H-1,2,3-triazoles derivatives are in equilibrium, 




2H-1,2,3-triazole  1H-1,2,3-triazole 
Figure.III.1 1,2,3-triazole tautomeric forms 2H-1,2,3-triazole and 1H-1,2,3-triazole 
(MarvinSketch 15.8.31) 
It is well known that compounds having an aza-hetero ring, such as triazole show 
inhibitory activity against aromatase [3]. 
QSAR methods are attempts to correlate the molecular structure or properties derived 
from the molecular structure with a particular type of chemical, biochemical or biological 
activity. [4-6] 
The present work reports ab initio and density functional results of molecular 
properties of 1H-1,2,3-triazole and 2H-1,2,3-triazole. Additionally, we applied DFT 
methods on some of 2H-1,2,3-triazole. We studied, at last, some of QSAR and drug 
likeness proprieties of 1,2,3 -triazole derivatives series reported in literature. On the other 
hand, calculated metrics aim to combine the potency with other parameters into a single 
metric which may be monitored during optimization. The earliest and most commonly 
applied metrics are the Ligand Efficiency (LE) and the Lipophilic Efficiency (LipE). Web 




2. MATERIAL AND METHODS 
All calculations were performed using HyperChem 8.0.6 software [7] Gaussian 09 
program package [8]; MarvinSketch 15.8.31 software [9], and Molinspiration online 
database, Molinspiration Cheminformatics [10].  
The geometries of 2H-1,2,3-triazole and 1H-1,2,3-triazole, were fully optimized with 
ab initio/HF (6-31G+, 6-31G++(d,p), 6-311G++(d,p))and DFT/B3LYP( 6-311++G (d, p)), 
integrated in Gaussian 09 program package. The calculation of QSAR properties is 
performed through the module QSAR Properties (HyperChem version 8.0.6), and allows 
the calculation of several properties commonly used in QSAR studies. 
Molinspiration, and web-based software was used to obtain parameter such as TPSA 
(topological polar surface area), nrotb (number of rotatable bonds) and drug likeness. The 
calculated results are reported in the present work. 
3. RESULTS AND DISCUSSION   
3.1 Geometric and electronic structure of 1 H-1,2,3-triazole  
The optimized geometrical parameters of 1H-1,2,3- triazole (Figure.III. 2) are 
obtained using ab-initio/HF and DFT methods, listed in (Table.III.1) and (Table III.2) with 
experimental results approximately similar to the theoretical results, regarding bond length 
and valence angle values [11]. 
 
 





Table III.1 Bond lengths (angstrom) of 1H-1,2,3-triazole 
Parameters EXP[7] 
Ab-initio/HF DFT/B3LYP 
6-31G+ 6-31G++(d,p) 6-311G++(d,p) 6-311G++ (d,p) 
N1-N2 1.355 1.346 1.448 1.315 1.349 
N2-N3 1.309 1.282 1.251 1.262 1.298 
N3-C4 1.370 1.372 1.402 1.356 1.364 
C4-C5 1.378 1.361 1.340 1.355 1.373 
C5-N1 1.356 1.352 1.317 1.343 1.355 
 
The theoretical dihedral angle values calculated by different methods are practically 
equal to zero degree explaining that the geometry of 1H-1,2,3- triazole is planar, and hence 
makes this conformation more stable. The charge densities calculated (Table III.3) by these 
methods are slightly different. 
Table III.2. Calculated values, valence angles and dihedral angles of 1H-1,2,3-triazole 
Parameters EXP[ 19] 
Ab initio/HF DFT/B3LYP 
6-31G+ 6-31G++(d,p) 6-311G++(d,p) 6-311 G ++ (d,p) 
N1-N2-N3 108.2 107.355 107.940 108.119 107.012 
N2-N3-C4 108.2 109.529 108.636 109.270 108.692 
N3-C4-C5 109.9 107.959 108.499 107.961 108.699 
C4-C5-N1 104.4 104.328 107.654 103.521 103.560 
C5-N1-N2 110.2 104.328 107.268 111.120 111.450 
N1-N2-N3-C4 - 0 0 0 0 
N2-N3-C4-C5 - 0 0 0 0 
N3-C4-C5-N1 - 0 0 0 0 
C4-C5-N1-N2 - 0 0 0 0 





Table III.3. Net charge distribution for 1H-1,2,3-triazole. 
Atoms Ab initio/HF DFT/B3LYP 6-311G++(d .p) 6-311++G(d,p) 
N1 -0.145 -0.051 
N2 -0.025 -0.044 
N3 -0.158 -0.158 
C4 -0.220 -0.160 
C5 -0.205 -0.210 
 
3.2 Geometric and electronic structure of 2 H-1,2,3-triazole 
The optimized geometrical parameters of 2 H-1,2,3-triazole by ab-initio/HF and DFT 
method listed in Table III.4 and Table III.5 are in accordance with numbering scheme given 
in Figure III.2. 
 
Table III.4. Bond lengths (angstrom) of 2H-1,2,3-triazole 
Parameters EXP[19] 
Ab initio/HF DFT/B3LYP 
6-31G+ 6-31G++(d,p) 6-311G++(d,p) 6-311G++(d,p) 
N1-N2 1.323 1.326 1.303 1.301 1.326 
N2-N3 1.323 1.326 1.303 1.301 1.326 
N3-C4 1.347 1.319 1.308 1.306 1.333 
C4-C5 1.401 1.411 1.404 1.405 1.406 






Table III.5. Calculated values of valence angles and dihedral angles of 2H-1,2,3-triazole 
Parameters EXP[19] Ab initio/HF DFT/B3LYP 6-31G+ 6-31G++(d,p) 6-311G++(d,p) 6-311++G(d,p) 
H5-C5-C4 130.8 121.897 121.742 130.349 130.293 
H4-C4-C5 130.8 121.897 121.742 130.349 130.293 
H2-N2-N3 - 122.698 122.001 122.019 121.094 
N1-N2-N3 117.3 114.604 115.997 115.951 116.55 
N2-N3-C4 - 104.569 104.084 104.152 103.111 
N3-C4-C5 - 108.129 107.918 108.612 108.612 
C4-C5-N1 - 108.129 107.918 108.612 108.612 
C5-N1-N2 - 104.569 104.084 104.152 103.111 
N1-N2-N3-C4 - -0.003 -0.001 0.001 0.008 
N2-N3-C4-C5 - -0.005 0.0000 0.002 -0.022 
N3-C4-C5-N1 - 0.012 0.002 0.002 0.030 
C4-C5-N1-N2 - 0.001 0.000 -0.001 0.022 
C5-N1-N2-N3 - 1.319 0.001 0.001 0.000 
 
The efficiency of theoretical methods may be assessed by comparison with 
experimental results [12]. From these results a good correlation can be seen between the 
ab-initio/HF, and DFT for bond length. We can also note that charge densities calculated by 
ab-initio/HF are approximately similar to those calculated by the DFT method (Table 
III.6).  
 
Table III.6. Net charge distribution for 2H-1,2,3-triazole. 
Atoms Ab initio/HF DFT/B3LYP 6-311G++(d .p) 6-311++G(d,p) 
N1 -0.129 -0.128 
N2 -0.063 -0.044 
N3 -0.129 -0.128 
C4 -0.188 -0.167 




The theoretical dihedral angle values calculated are practically equal to zero degree 
revealing that the geometry of 2H-1,2,3-triazole is planar, and hence makes this 
conformation more stable. 
The efficiency of DFT/B3LYP method with 6-311++G(d,p) basis set may be 
scrutinized by comparison with the results obtained by ab-initio/HF method. A very good 
agreement between predicted geometries (bond lengths and bond angles) and 
corresponding experimental data, especially the DFT/B3LYP results can be observed. 
From that, we can say that the DFT method is more appropriate for further study on 
1,2,3-triazole derivatives in other parts of this work. 
To compare the stability of the two compounds 1H-1,2,3-triazoleand 
2H-1,2,3-triazole, we calculated the HOMO (highest occupied molecular orbital), and the 
LUMO (lowest unoccupied molecular orbital) and their difference (ΔE) calculated by 
DFT/6-311G (d,p) by (Gaussian09) and heat of formation, calculated by (HyperChem 8.06) 
the results are reported in Table III.7. 
 
Table III.7. Calculated EHOMO, ELUMO, energy band gap (ΔE) and Heat of formation ΔHf 







1H-1.2.3 triazole -0.279 -0.023 0.256 67.813 
2H-1.2.3 triazole -0.289 -0.026 0.263 70.610 
 
The calculations show the 2H tautomer as the more stable with a low reactivity. The 
difference of ΔE1H-2H was -2.1kcal·mol-1. These results agreed the results obtained by 





3.3 Molecular electrostatic potential 
The molecular electrostatic potential is a well-established tool to explain the reactive 
behavior of a wide variety of chemical systems in both electrophilic and nucleophilic 
reactions. The study of biological recognition processes and hydrogen bonding interactions 
was performed to predict the reactive sites for electrophilic and nucleophilic attack for the 







Figure. III.  3 D MESP surface map and 2D MESP contour map for 2H 1,2,3 triazole 





The MEP is a useful property to study reactivity given that an approaching 
electrophile will be attracted to negative regions (where the electron distribution effect is 
dominant) [15]. The electrostatic potential values are represented by different colors. The 
positive, negative and neutral electrostatic potential regions of molecules are shown in 
terms of color grading. Generally, potential increases in the order red < orange < yellow < 
green < blue. The red color indicates the maximum negative region and the blue color 
represents the maximum positive region [16,17]. 
The MESP surface map (Figure III.3) for 2H-1,2,3-triazole shows that the maximum 
negative region is localized (yellow) over N1, N3 atoms and the maximum positive region 
is localized on NH group (bleu), indicating a possible site for nucleophilic attack. These 
sites give information about the region from which the compound can has intermolecular 
interactions. This predicted the most reactive site for both electrophilic and nucleophilic 
attack [18]. 
The green color situated in the middle between the yellow and blue regions and 
localized on CH groups explains the neutral electrostatic potential surface. 
 
3.4 Substitution effect on 2H-1,2,3-triazole structure 
To perceive the effect of the substitution, we have studied two series: the methyl and 
the ethyl group for the first series (an electron donor group), the cyanide and Chloride 
group for the second series (an electron attractor group) in position N2, C4 and C5 in the 



















-0.289 -0.026 0.263 0.217 70.610 
Series 1 
T1 -0.272 -0.021 0.251 0.485 69.068 
T2 -0.272 -0.018 0.252 0.700 61.168 
T3 -0.272 -0.018 0.252 0.700 61.168 
T4 -0.258 -0.015 0.243 0.343 59.688 
T5 -0.258 -0.015 0.243 0.343 59.688 
T6 -0.259 -0.011 0.248 0.908 51.918 
T7 -0.270 -0.020 0.250 0.658 64.308 
T8 -0.272 -0.020 0.251 0.398 56.550 
T9 -0.272 -0.020 0.251 0.741 56.550 
T10 -0.256 -0.016 0.240 0.741 50.581 
T11 -0.256 -0.016 0.240 0.504 50.585 
T12 -0.258 0.013 0.271 0.810 43.195 
T13 -0.246 -0.010 0.236 0.508 50.195 
T14 -0.245 -0.016 0.229 0.285 36.101 
Series 2 
T`1 -0.285 -0.071 0.214 1.331 74.510 
T`2 -0.281 0.038 0.243 1.217 65.360 
T`3 -0.281 0.038 0.243 1.217 65.360 
T`4 -0.281 -0.081 0.200 0.838 69.425 
T`5 -0.279 -0.048 0.231 1.620 60.687 
T`6 -0.281 -0.081 0.200 0.838 69.425 
T`7 -0.311 -0.084 0.227 4.883 121.960 
T`8 -0.308 -0.068 0.240 4.062 108.150 
T`9 -0.308 -0.068 0.240 4.062 108.150 
T`10 -0.329 -0.118 0.211 2.750 161.290 
T`11 -0.325 -0.092 0.233 5.762 148.050 
T`12 -0.329 -0.118 0.211 3.059 161.290 
T`13 -0.343 -0.140 0.203 1.327 202.590 
T`14 -0.279 -0.091 0.188 0.545 64.910 
Heat of formation, dipole moment, HOMO (highest occupied molecular orbital), 
LUMO (lowest unoccupied molecular orbital) and their difference (ΔE) are reported for 








Table III.9. Mulliken charges of 2H-1,2,3-triazole and its derivatives (series 1) 
Series1 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 
N1 -0.12 -0.15 -0.15 -0.06 -0.06 -0.12 -0.31 -0.12 -0.05 -0.10 -0.10 -0.08 -0.05 -0.25 
N2 0.10 -0.1 -0.01 0.12 0.12 -0.01 0.27 0.02 0.02 0.30 0.30 -0.33 0.06 0.42 
N3 -0.12 -0.11 -0.11 -0.14 -0.14 -0.12 -0.31 -0.12 -0.12 -0.10 -0.10 -0.12 -0.05 -0.31 
C4 -0.17 -0.09 0.09 0.04 0.04 0.10 -0.2 0.14 -0.26 0.12 0.12 0.14 0.13 0.17 
C5 -0.17 0.09 -0.09 -0.06 -0.06 0.10 -0.2 -0.26 0.15 -0.24 -0.24 -0.23 0.10 0.02 
Sub 
N2 
C1-methyl -0.31 - - 0.29 0.29 - - - - - - - 0.28  
C1-ethyl - - - - - - 0.15 - - -0.27 -0.27 - - -0.17 
C2-ethyl - - - - -  -0.65 - - -0.44 -0.44 - - -0.60 
Sub 
C4 
C1-methyl - -0.70  -0.70 - -0.61 - - - - - - -0.69 - 
C1-ethyl - - - - - -  -0.38 - -0.42 - -0.29 - -0.48 
C2-ethyl - - - - - - - -0.51 - -0.53 - -0.63 - -0.65 
Sub 
C5 
C1-methyl -  -0.70  -0.74 -0.61 - - - - - - -0.69 - 
C1-ethyl - - - - - - - - -0.38  -0.42 -0.18 - -0.48 








Sub N Substitution is in the atom N2, Sub C4 Substitution is in the atom C4, Sub C5 Substitution is in the atom C5 
 
Table III.10. Mulliken charges of 2H-1,2,3-triazole and its derivatives (series 2). 
 
Series2 T’1 T’2 T’3 T’4 T’5 T’6 T’7 T’8 T’9 T’10 T’11 T’12 T’13 T’14 
N1 -0.09 -0.04 -0.09 -0.06 -0.01 -0.01 -0.08 -0.11 -0.12 -0.03 -0.10 -0.04 -0.01 0.04 
N2 0.34 -0.04 -0.04 0.35 -0.07 0.35 0.08 0.06 0.06 0.15 0.04 0.15 0.14 0.34 
N3 -0.09 -0.09 -0.04 -0.01 -0.01 -0.06 -0.08 -0.12 -0.11 -0.04 -0.10 -0.03 -0.01 0.04 
C4 -0.17 -0.37 -0.24 -0.36 -0.53 -0.31 -0.14 0.02 0.72 0.74 0.89 0.01 0.99 -0.56 
C5 -0.17 -0.24 -0.37 -0.31 -0.53 -0.36 -0.14 0.72 0.02 0.01 0.89 0.74 0.99 -0.56 
Sub 
N2 
Cl 0.13 - - -0.10 - -0.10 - - - - - - - -0.09 
C-cyano - - - - - - 0.22 - - 0.22 - 0.22 0.22 - 
N-cyano - - - - - - 0.20 - - -0.18 - -0.18 -0.16 - 
Sub 
C4 
Cl - 0.31 - - 0.40 0.31 - - - - - - - 0.39 
C-cyano - - - - - - - - -0.91 -0.89 -0.83 - -0.94 - 
N-cyano - - - - - - - - -020 -0.18 -0.15 - -0.14 - 
Sub 
C5 
Cl - - 0.31 0.31 0.40 - - - - - - - - 0.39 
C-cyano - - - - - - - -0.91 - - -0.83 -0.89 -0.94 - 





Net atomic charges are also reported for the effect of the substitution on the 
electronic parameters and energy and their impact on the stability and chemical reactivity 
of molecule. Two series substituted molecule were studied (Figure III.4). This calculation 
is performed by DFT/B3LYP method using 6-311++G (d,p) basis set. 
The heat of formation decreased approximately to 2 and 7 kcal·mol-1 at each 
addition of methyl and ethyl groups respectively. Compounds T1, T4, T7 (nitrogen 
substituent) were the greatest values of the heat of formation compared to other 
derivatives. 
N 2 substituted 1,2,3-triazoles are one special class of triazole derivatives [19] 
.  
Series1 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 
R1 CH 3 H H CH 3 CH 3 H C2H5 H H C2H5 C2H5 H CH 3 C2H5 
R2 H CH 3 H CH 3 H CH 3 H C2H5 H C2H5 H C2H5 CH 3 C2H5 
R3 H H CH 3 H CH 3 CH 3 H H C2H5 H C2H5 C2H5 CH 3 C2H5 
 
              
Series2 T`1 T’2 T’3 T’4 T’5 T’6 T’7 T’8 T’9 T’10 T’11 T’12 T’13 T’14 
R1 Cl H H Cl Cl H CN H H CN H CN CN Cl 
R2 H Cl H Cl H Cl H CN H H CN CN CN Cl 
R3 H H Cl H Cl Cl H H CN CN CN H CN Cl 
Figure III. 4. 2H-1,2,3-triazole systems (Marvin sketch 15.8.31) 
 
The Highest occupied molecular orbital (HOMO) and the lowest un-occupied 
molecular orbital (LUMO) are very important parameters for quantum chemistry. These 
values help to exemplify the chemical reactivity and kinetic stability of the molecule. The 
HOMO represents the ability to donate an electron and the LUMO as electron acceptor 





In order to evaluate the energetic behavior of the title compound, the relatively high 
value of ΔEHOMO–LUMO indicates that the title compound presents high chemical stability 
and low reactivity [20,21]. Reactive (HSAB principle: hard and soft acids and bases), Hard 
bases have highest-occupied molecular orbitals (HOMO) of low energy, and hard acids 
have lowest-unoccupied molecular orbitals (LUMO) of high energy [22,23]. 
In the mono-substituted Methyl group category, the compound T1 shows a maximum 
positive charge on nitrogen (0.1) leading to a nucleophilic substitution (Table III.9). 
In the case of dimethyl and diethyl substitution of 2H-1,2,3-triazole in the N2 
position compound T4 and T10 show maximum charge (0.12) and (0.30) respectively and 
smaller HOMO-LUMO energy gap (0.243) and (0.240) respectively (Table III.9) and leads 
to preferential site of nucleophilic attack. We also note that the methyl and ethyl 
substituent (donor effect) in (Table III.8) has the effect of increasing the energy of the 
HOMO, with little change in the LUMO. 
From the results shown in Table 4, the 4,5-dimethyl1,2,3-triazole (compound T6) 
shows an important dipole moment value (0.908 D). It is the most soluble in polar solvents 
than other derivatives. 
In the present work, we have studied cyanide and Chloride substituted 1,2,3-triazole 
along the same line of methyl and ethyl substituted 2 H-1,2,3-triazole for a comparative 
study. 
The heat of formation increased approximately 4 and 51 kcal·mol-1 at each addition 
of Chloride and cyanide groups respectively. 
In mono-substituted cyanide and chloride derivatives, 2-chloro-1,2,3-triazole 
(compound T’1) is predicted to be more chemically reactive than 
4-Cyano-1,2,3-triazole,2-Cyano- 1,2,3-triazole and 4-Chloro- 1,2,3-triazole on the basis of 





Indi-substituted cyanide and chloride derivatives, dichloro 1,2,3-triazole (compounds 
T’4and T’6) is more reactive than dicyano 1,2,3-triazole (compound T’10). this is due to 
smaller HOMO-LUMO energy gap (0.200) (Table III.8). 
The compound T’4 and T’6 is predicted to be the most reactive with smaller 
HOMO-LUMO energy gap of all 1,2,3-triazole systems (except the tri-substituted 
compounds). 
The study of the effect of substitution on the 1.2.3 triazole base groups electron 
donor group and electron attractor group shows that by comparing the LUMO - HOMO 
gaps, the most chemically active are the tri-substituted. CompoundsT`14 and T14 show 
maximum charge in the N2 position (0.42) and (0.34) respectively. These results are in 
close agreement with the experiment, whereas the majority of tri-substituted 1,2,3-triazole 
have biological activity [24-26]. 
We note also that the cyanide and chloride substituent (attractor effect) lowers the 
energies of HOMO and LUMO. The influence on the energy of the LUMO is more 
important. 
The effective atomic charges calculation which depicts the charges of every atom in 
the molecule distribution of positive and negative charges are vital to increase or decrease 
in bond length between the atoms, atomic charges, effect dipole moments, molecular 
polarizability, electronic structure, acidity-basicity behavior properties of molecular system 
and electrostatic potential surfaces [27,28]. 
The compound T`14 is predicted to be the most reactive with smaller HOMO-LUMO 
energy gap and with the most important positive charge on nitrogen N2. This Nitrogen is 
preferred for nucleophilic attack. 
Based on our conclusions on the effect of substitution on the1,2,3-triazole molecule. 





3.5 Structure activity/property relationships of aromatase inhibitory activity of 
substituted 1,2,3-triazole 
For the series of 1,2,3-triazole derivatives (Figure III.5) we have studied seven 
physicochemical properties with respect to their biological activities i.e, aromatase 
inhibitory activity [29]. The properties involved are: surface area grid (SAG), molar 
volume (V), hydration energy (HE), partition coefficient octanol/water (logP), molar 
refractivity (MR), polarizability (Pol) and molecular weight (MW). The results obtained 
using HyperChem 8.0.6 software are shown in Table III.11 and Table III.12. For example, 
figure III.6 shows the favored conformation in 3D of the compound 11. 
Table III.11 . QSAR proprieties for 1,2,3-triazole derivatives 










1 748.96 465.70 -11.47 25.74 75.13 
2 907.17 557.73 -10.40 31.25 88.93 
3 1063.73 633.76 -17.14 41.98 123.41 
4 836.96 502.85 -10.09 30.47 87.00 
5 802.85 500.60 -13.67 29.90 90.01 
6 889.17 547.10 -15.81 32.37 96.62 
7 936.17 575.25 -15.48 34.30 101.34 
8 950.02 582.33 -19.98 34.22 101.60 
9 942.17 577.93 -14.68 34.20 100.90 
10 911.32 561.11 -22.74 33.00 98.23 
11 1097.37 663.18 -16.62 42.03 125.14 
12 1089.77 632.87 -13.87 41.98 120.40 
13 849.89 526.55 -6.26 29.39 243.35 
14 1010.69 609.48 -14.54 37.25 108.53 
15 787.34 481.85 -5.46 28.62 82.06 
16 746.55 467.42 -9.53 28.04 85.03 
17 835.52 517.36 -11.78 30.52 91.64 
18 882.86 544.68 -10.49 32.35 95.92 
19 855.60 523.83 -18.77 31.15 93.25 
20 876.54 539.32 -11.40 32.44 96.36 
21 889.10 549.66 -15.94 32.37 96.62 




Table III.12. Drug likeness scoring for compounds 
 Lipinski rules Veber rules Ligand efficiency and Lipophilicity efficiency 
Compounds Log P MW HBD HBA 
NVIOLAT
ION 
nrotb TPSA ABS pIC50[41] LE LipE 
1 1.61 226.28 4 0 0 4 54.51 90.19 5.36 0.44 3.75 
2 2.80 268.36 4 0 0 7 54.51 90.19 5.26 0.36 2.46 
3 3.60 327.39 5 0 0 4 78.30 81.98 4.99 0.24 1.39 
4 2.30 266.35 4 0 0 3 54.51 90.19 4.97 0.40 2.67 
5 1.42 260.30 4 0 0 3 54.51 90.19 5.47 0.38 4.05 
6 0.83 290.32 5 0 0 5 63.74 87.00 5.22 0.36 4.39 
7 0.61 324.77 5 0 0 5 63.74 87.00 5.41 0.36 4.8 
8 0.55 315.33 6 0 0 5 87.54 78.79 5.04 0.32 4.49 
9 0.90 304.35 5 0 0 5 63.74 87.00 5.38 0.32 4.48 
10 0.20 306.32 6 0 0 6 72.98 83.82 5.63 0.35 5.83 
11 1.44 366.42 5 0 0 6 63.74 87.00 4.94 0.30 3.5 
12 3.11 367.45 5 0 0 4 78.30 81.98 4.71 0.23 1.6 
13 3.08 243.35 3 0 0 7 30.72 98.40 5.02 0.25 1.94 
14 2.42 327.39 5 0 0 5 78.30 81.98 5.33 0.41 2.91 
15 2.85 241.34 3 0 0 3 30.72 98.40 5.10 0.28 2.25 
16 1.69 235.29 3 0 0 3 30.72 98.40 5.01 0.38 3.32 
17 1.11 265.31 5 0 0 6 39.95 95.21 4.97 0.41 3.86 
18 1.26 279.34 4 0 0 5 39.95 95.21 5.65 0.39 4.39 
19 0.08 281.31 5 0 0 6 49.19 92.02 4.76 0.31 4.68 
20 0.88 299.76 4 0 0 5 39.95 95.21 5.30 0.33 4.42 
21 0.83 290.32 5 0 0 5 63.74 87.00 5.87 0.39 5.04 






QSAR (Quantitative Structure-Property Relationships) deals with relationship 
between physico-chemical properties & chemical structure, are based on the assumption 
that the structure of a molecule (i.e, its geometric, steric and electronic properties) must 
contain the features responsible for its physical, chemical, and biological properties and on 
the ability to represent the chemical by one or more numerical descriptors [30,31]. The 
relationships between the physicochemical properties of drugs and pharmacokinetic 
processes have been extensively studied. Some physicochemical parameters of drugs, such 
as lipophilicity, hydrogen-bonding capacity, molecular size and polar surface area, have 
proved to be useful for predicting passive transfer and permeation across biomembranes in 
ADME, but none has attracted as much interest in quantitative structure-permeation 
relationship (QSPeR) studies as lipophilicity [32]. 
Molecular volume determines transport characteristics of molecules, such as 
intestinal absorption or blood-brain barrier penetration [33]. Volume is therefore often used 
in QSAR studies to model molecular properties and biological activity. 
Molecular weight (MW) is related to the size of the molecule. As molecular size 
increases, a larger cavity must be formed in water in order to solubilize the compound. 
Increasing MW reduces the compound concentration at the surface of the intestinal 
epithelium, thus reducing absorption. Increasing size also impedes passive diffusion 
through the tightly packed aliphatic side chains of the bilayer membrane [34]. 
Hydration energy is a key factor determining the stability of different molecular 
conformations in water solutions. 
The molar refractivity is a steric parameter that is dependent on the spatial array of 
the aromatic ring in the synthesized compounds. The spatial arrangement also is necessary 
to study the interaction of the ligand with the receptor. Molar refractivity is related, not 
only to the volume of the molecules but also to the London dispersive forces that act in the 





The polarizability of an atom or molecule describes the response of its electron cloud 
to an external field. Polarizability appears in many formulas for low-energy processes 
involving the valence electrons of atoms or molecules. It is also widely used to describe the 
inductive and dispersive interactions of a molecule or molecular system, and it plays an 
important role in modeling many molecular properties and biological activities [35]. 
The values of polarizability are generally proportional to the values of surfaces and 
of volumes. We observe that polarizability data are generally proportional to refractivity, 
molecular volume and surface. Compound 11 shows the maximum value of both 
polarizability (42.03 Å³) and refractivity (125.14Å³). This compound has also high values 
of molecular weight (366.42), volume (1097.37 Å³) and surface (663.18Å2). 
The most important hydration energy in the absolute value is that of the compound 
10 (22.74 kcal·mol-1) and the weakest is that of compound 15 (5.46 kcal·mol-1) (Table 
III.11). 
In fact, in the biological environments the polar molecules are surrounded by water 
molecules. Hence hydrogen bonds are established between a water molecule and these 
molecules.  
Hydrophobic groups in 1,2,3- triazole derivatives induce a decrease of hydration 
energy. However, the lipophilicity increases proportionally with the hydrophobic features 
of substituent. As seen in Table III.9, the compound 10 is expected to have the highest 
hydrophilicity, whereas compound 15 will be most Lipophilic. This implies that these 
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Figure III.5. 2D structures of 1,2,3-triazole derivatives 
 
 
Figure. III.6. 3D conformation of compound 11 (HyperChem 8.03) 
 
3.6 Drug-likeness properties of 1,2,3-triazole derivatives 
Structures of all the selected 1,2,3-triazole derivatives in Figure III.5, were fed in the 
online Molinspiration software version (www.molinspiration.com) for calculation of 
molecular properties (number of hydrogen bond donors and acceptors, molecular weight) 





Lipophilicity is usually measured by the partition coefficient (log P) of a compound 
in a single electrical form of molecular. It is a parameter that describes the partition 
equilibrium of a solute between water and an immiscible organic solvent. Log P is one 
criterion used in medicinal chemistry to assess the drug likeness of a given molecule, and 
is used to calculate lipophilic efficiency: a function of potency and log P that evaluate the 
quality of research compounds. For a given compound lipophilic efficiency is defined as 
the pIC50 (or pEC50) of interest minus the log P of the compound [36]. 
Molecular polar surface area (PSA), surface belonging to polar atoms, is a descriptor 
shown to correlate well with passive molecular transport through membranes and, 
therefore, allows prediction of transport properties of drugs. The calculation of PSA, 
however, is rather time-consuming because of the necessity to generate a reasonable 3D 
molecular geometry and the calculation of the surface it self.  Molecules with PSA values 
of 140 A0 or more are expected to exhibit poor intestinal absorption [37]. TPSA was used 
to calculate the percentage of absorption (%ABS) according to the equation (1) [38]. 
TPSAABS  345.0109%         (1) 
The LogP values for all compounds 1,2,3-triazole derivatives except 3 (which has the 
higher value 3.60) are in the field of optimal values (0˂ Log P ˂3) so we could say that 
these compounds have optimal biological activity (permeability, solubility). For a too high 
log P, the drug has low solubility and a too low Log P so it has difficulty penetrating the 
lipid membranes. Therefore the different properties which describe a molecular are so 
important for a drug's pharmacokinetics in the human body, including absorption, 
distribution, metabolism, and excretion "ADME" Components of the Lipinski's rule. [39]  
However, there are some exceptions to this rule and a compound is likely to be orally 
active as long as it did not break more than one of its rules because some of orally active 





The calculation results show that all compounds meet the Lipinski rules. The 
suggesting log P of these compounds was found below 5 which means a good permeability 
across cell membrane: TPSA below 140 Ǻ2, n violations =1 or <0 it means compound 
easily bind to receptor, molecular mass <500, nrotb < 5, H-bond donors (HBD) ≤ 5 and 
H-bond acceptors (HBA) ≤ 10. [40] 
In our case, the Lipinski and Veber rules are validated, therefore, theoretically, there 
would not have a problem with oral bioavailability for all chosen compounds. 
TPSA of 1,2,3-triazole derivatives were found in the range of 87.54- 30.72 and were 
well below the 140 Å2. We can observe obviously that all the title compounds (1–22) 
exhibited a great %ABS ranging from 78.79 to 98.40% indicating that these compounds 
should have good cellular plasmatic membrane permeability (Table III.12). 
Ligand lipophilicity efficiency (LEE or LipE) is a ligand efficiency index that was 
first proposed by Leeson and Springthrope. LipE provides a straightforward and 
meaningful way to evaluate the quality of research compounds, linking potency and 
lipophilicity in an attempt to estimate drug-likeness, LipE attempts to maximize the 
minimally acceptable lipophilicity per unit of in vitro potency or more simply, to improve 
potency, while maintaining low lipophilicity. 
50 logLipE pIC P 
    (2) 
LipE is defined as the difference of logP (or log D) and the negative logarithm of a 
potency measure (pKd, pKi or pEC50) [41]. 
In addition, we have studied the Ligand Efficiency (LE) to penalize large compounds 
over small compounds with similar potency because larger compounds tend to have poorer 
physicochemical and ADME properties. 
The LE metric was first defined by Andrews, which defines it as biological activity 
per molecular size. 
1.4 50 HLE pIC N     (3) 




Ligand efficiency is a simple metric for assessing whether a ligand derives its 
potency from optimal fit with the target protein or simply by virtue of making many 
contacts. 
It shows generally a dependency on ligand size i.e. Ligand efficiency drops 
dramatically when the size of the ligand increases [42-44]. 
We can see through the results in Table III.12 that compound 10 had the highest LipE 
and LE value of the data set and was deemed to be the most optimal compound. 
 
4. CONCLUSION  
The present work studied the molecular proprieties of 1,2,3-triazole. The DFT and 
ab-initio/HF methods can be used quite satisfactorily in predicting the chemical reactivity 
of the molecules and the effect of substitution of either donor or acceptor electron. 
The calculations show the 2H tautomer to be the more stable with low reactivity, and 
difference of ΔE1H-2H= -2.1kcal/mol. 
The study of substitution on the 1.2.3-triazole base groups (electron donor group and 
electron attractor group) shows that by comparing the LUMO - HOMO gaps, the most 
chemically active compounds are found to be the trisubstituted T`14 and T14.1,2,3-triazole 
derivatives exhibited a great  %ABS and thus reflecting a good cellular plasmatic 
membrane permeability. 
Compound 19 in the series of 1,2,3- triazole derivatives, presents a low coefficient of 
division (logP), hence it is the most absorbent product. 
Compound 10 has an important hydration energy leading to a better distribution in 
fabrics. Moreover, it had the highest LipE and LE values of the data set that's why it was 
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QSAR MODEL FOR PREDICTING 
THE AROMATASE INHIBITION 







Breast cancer is a kind of malignant tumor for women, [1] which accounts about 30% 
incidences for all malignant tumors in different age groups of women. In recent years, the 
mortality rate of breast cancer also shows an increasing trend and it has become one of the 
major causes of cancer death in female. [2] 
A great majority of breast cancers is hormone-dependent [3] and it is widely accepted 
that estrogen plays an important role in the genesis and evolution of breast tumors. [4] 
Aromatase (CYP19) a cytochrome P450 enzyme, is responsible for the conversion of 
androgens including androstenedione and testosterone into estrogens, [5] therefore it is 
considered as a particularly attractive target for inhibition in the endocrine treatment of 
hormone-dependent breast cancer. Non-steroidal aromatase inhibitors, such as 
aminoglutethimide [6] anastrozole (Arimidex™) [7] and letrozole (Femara™).[8] 
Competitively inhibit the enzymatic activity of aromatase in a reversible manner and play 
an important role in the endocrine treatment for hormone-dependent breast cancers. 
Among the AIs (inhibitory aromatase). letrozole and anastrozole both containing 
1.2.4-triazole ring, were approved by the Food and Drug Administration (FDA) and using 
as the first-line therapy in the treatment of breast cancer in postmenopausal women since 
they have been shown to be superior to tamoxifen. [[9, 10] Based on the AIs, the triazole 
ring plays a pivotal role in chelation with heme iron. [11,12]  
The results revealed that 1.2.3-trizole analog of letrozole showed equipotent activity 
to the parent compound. 
In last decades, quantitative Structure-Activity Relationships (QSAR), [13] have been 
applied in many areas enabling to prevent time consuming and cost during the analysis of 
biological activities of interest. The main hypothesis involved in any QSAR is the 
assumption that the variation of the behavior of chemical compounds, as expressed by any 
experimentally measured biological or physicochemical property, can be correlated with 
numerical entities related to some aspect of the chemical structure termed molecular 
descriptors. [14-16] 
 Descriptors are generally used to describe different characteristics/ attributes of the 
chemical structure in order to yield information about the activity/property being studied. 
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Herein, a series of 1-substituted mono- and bis-benzonitrile or phenyl analogs of 1.2.3-
triazole letrozole are employed for QSAR modeling of the aromatase inhibitory activity. A 
diverse set of quantum chemical and molecular descriptors were employed to provide 
numerical description of the investigated compounds, using multiple linear regressions 
(MLR). 
2. MATERIALS AND METHODS 
2.1 Data set 
A series of thirty molecules belonging to 1.2.3-triazole derivatives have aromatase 
inhibitory activity, were taken from literature. [17] the studied compounds were randomly 
divided into training set (twenty-four compounds) and test set (six compounds). Training 
and test set compounds are represented in (figure.IV.1). These compounds in the series were 
sketched using ChemDraw module which is available in ChemOffice.  
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2.2 Descriptors generation 
Firstly, the thirty investigated molecules were pre-optimized by the Molecular 
Mechanics Force Field (MM+) included in HyperChem version 8.03 package. [19] After 
that, the resulted minimized structures were further refined using the semi empirical PM3 
Hamiltonian implemented also in HyperChem.We chose a gradient norm limit of 0.01kcal/Å 
for the geometry optimization.  
QSAR properties module from HyperChem 8.03 was used to calculate physical and 
chemical proprieties of a series of thirty 1.2.3-triazole derivatives: the molar polarizability 
(Pol), the molar refractivity (MR), partition coefficient octanol/water (log P), hydration 
energy (HE) , molar volume (MV) , Surface area grid (SAG) and molar weight (MW); these 
properties are described in (table IV.1).  
Then, these 1.2.3 triazoles were reoptimized by using Gaussian 09 program package. 
[20] At the density functional theory level (DFT) using Becke’s three-parameter Lee-Yang- 
Parr (B3LYP) With the 6-311G (d. p) basis set, this theory was used to calculate a number 
of electronic descriptors such as; HOMO and LUMO energies and atomic net charges (qN1, 
qN2,qN3,qC4 and qC5).(table IV.2) 
Molinspiration web [22] based software was used to obtain TPSA parameter 
(topological polar surface area) which was used to calculate the percentage of absorption 
(%ABS) according to the equation [23]: %ABS =  109 ±  0.345 × TPSA                  
Also, we calculated the Ligand Efficiency (LE) according to the equation: 𝐿𝐸 = 1.4𝑝𝐼𝐶50/𝑁𝐻                                     







Table VI.1.  Physicochemical descriptors. 
 S (A°2) M(uma) EH(kcal/mol) pol(A°3) ref(A°3) TPSA ABS LE Log P 
1 458.7 246.27 -14.22 28.06 85.85 87.5 90.19 0.380 0.89 
2 510.0 287.28 -21.48 30.55 91.44 96.7 78.79 0.320 1.11 
3 507.0 276.30 -16.11 30.53 90.74 87.5 87.00 0.320 1.54 
4 520.1 292.30 -18.99 31.17 92.83 49.1 83.82 0.350 0.39 
5 516.9 338.37 -18.15 38.36 114.9 30.7 87.00 0.300 1.99 
6 621.7 258.43 -5.25 34.90 98.20 30.7 81.98 0.410 4.14 
7 450.9 227.31 -6.36 26.78 77.86 30.7 98.400 0.280 2.06 
8 469.2 251.29 -11.96 28.68 85.76 63.7 95.210 0.390 1.82 
9 520.5 285.31 -17.81 93.62 31.75 78.3 81.987 0.515 1.52 
10 609.4 327.39 -14.54 108.5 37.25 78.3 81.987 0.265 2.42 
11 822.9 425.52 -11.87 140.7 50.10 87.5 78.799 0.231 5.19 
12 632.8 367.45 -13.87 120.4 41.98 87.5 78.799 0.216 3.11 
13 633.7 361.40 -17.14 123.4 41.41 111. 70.591 0.233 2.22 
14 660.4 377.40 -18.88 124.0 42.05 96.7 75.614 0.215 2.71 
15 683.0 411.85 -18.50 128.7 43.97 87.5 78.799 0.189 2.49 
16 702.0 407.430 -20.50 130.4 44.52 49.1 92.029 0.241 1.72 
17 747.0 453.500 -20.86 152.5 51.74 30.7 98.402 0.415 3.32 
18 454.7 235.29 83.66 28.04 0.331 30.7 98.402 0.331 2.08 
19 544.1 277.370 98.57 33.55 0.282 30.7 98.402 0.282 2.97 
20 629.8 319.450 112.3 39.05 0.285 30.7 98.402 0.285 4.16 
21 570.5 311.390 113.4 37.70 0.284 30.7 98.402 0.284 2.78 
22 588.6 317.430 110.4 38.28 0.243 39.9 95.217 0.243 3.66 
23 614.8 361.830 118.7 40.27 0.239 63.7 87.010 0.239 3.05 
24 627.5 352.400 119.0 40.19 0.237 39.9 95.217 0.237 2.99 
25t 442.2 212.25 23.91 70.97 0.44 78.3 81.98 0.44 1.09 
26t 653.1 310.44 36.78 103.1 0.24 39.9 95.21 0.24 3.86 
27t 701.0 369.47 42.76 122.3 0.21 78.3 81.98 0.21 3.6 
26t 642.4 375.86 42.1 124.7 0.25 39.9 95.21 0.25 1.97 
29t 549.6 290.32 32.37 96.62 0.373 63.4 87 0.373 0.83 





Table IV.2.  Electronic descriptors 
 ELUMO qN1 qN2 qC4 qC5 
1 -0.06 -0.49 -0.001 0.01 0.21 
2 -0.09 -0.49 -0.012 0.05 0.22 
3 -0.06 -0.49 -0.017 0.06 0.22 
4 -0.06 -0.49 -0.017 0.28 0.22 
5 -0.08 -0.70 0.019 0.27 0.25 
6 -0.07 -0.48 -0.023 0.10 0.18 
7 -0.01 -0.49 -0.016 0.11 0.17 
8 -0.01 -0.49 0.023 0.08 0.17 
9 -0.07 -0.68 0.007 0.28 0.22 
10 -0.07 -0.49 -0.023 0.10 0.18 
11 -0.07 -0.48 -0.019 0.36 0.18 
12 -0.07 -0.49 -0.010 0.09 0.20 
13 -0.07 -0.49 -0.006 0.09 0.21 
14 -0.07 -0.49 -0.015 0.09 0.20 
15 -0.07 -0.49 -0.015 0.09 0.21 
16 -0.02 -0.48 -0.007 0.09 0.28 
17 -0.01 -0.48 -0.019 0.09 0.18 
18 -0.02 -0.49 -0.003 0.018 0.21 
19 -0.01 -0.49 -0.013 0.11 0.17 
20 -0.02 -0.47 -0.010 0.36 0.18 
21 -0.02 -0.47 -0.005 0.36 0.10 
22 -0.03 -0.52 0.034 0.04 0.22 
23 -0.03 -0.48 -0.002 0.09 0.20 
24 -0.02 -0.47 -0.010 0.36 0.18 
25t -0.25 -0.5 -0.005 -0.29 0.01 
26t -0.26 -0.49 0.017 -0.06 0225 
27t -0.07 -0.49 -0.02 0.101 0.18 
26t -0.02 -0.48 -0.001 0.098 0.20 
29t -0.04 -0.49 -0.011 0.05 0.27 




2.3 Regression analysis  
Multiple linear regression analysis of molecular descriptors was carried out using the 
stepwise strategy in SPSS version 19 for Windows. [25] 
2.4 Validation of the QSAR model 
Testing the stability predictive power and generalization ability of the models is a very 
important step in QSAR study, as for the validation of predictive power of a QSAR model. 
two basic principles (internal validation and external validation) are used. 
3. RESULTS AND DISCUSSION  
In the present study we tried to developed the best QSAR model to explain the 
correlations between the physicochemical parameters and the biological activities IC50 
values of 1.2.3 triazole derivatives with aromatase inhibitory effects. 
The full linear equation for the prediction of the inhibitory IC50 activity is the following 
equation                                     
 
n = 24 ; R = 0.991 ; R2 = 0.982; S = 0.149 ; F = 34.569 ; Q = 6.651 
The significant equation consists of 14 descriptors; polarizability (Pol), the molar 
refractivity (ref), partition coefficient octanol/water (log P), hydration energy (HE), Surface 
area grid (S), molar weight (M), TPSA (topological polar surface area), the percentage of 
absorption (%ABS), Ligand efficiency (LE), ELUMO and atomic net charges (qN1, qN2, qC4, 
qC5). 
The F-value has found to be statistically significant at 95 % level since the calculated 
F value is higher as compared to tabulated value.  
The positive value of quality factor (Q) for this QSAR’s model suggests its high 
predictive power and lack of over fitting. 
The positive coefficient of hydration energy and negative Log P indicates that the 
hydrophilic derivatives give a good biological activity. 
From the equation, we can see any increase in the molecular surface causes an increase 
of the biological activity, which results in increased surface of contact between the ligand 
𝑝(𝐼𝐶50) = 2.726 + 0.005𝑆 − 0.366𝑙𝑜𝑔𝑃 − 0.026𝑟𝑒𝑓 + 6.894𝐿𝐸 − 6.604𝑞𝑁1 + 0.01𝑇𝑃𝑆𝐴+ 0.057𝐸𝐻 + 9.431𝐸𝐿𝑈𝑀𝑂 − 5.333𝑞𝑁2 + 0.722𝑞𝐶4 − 0.026𝐴𝐵𝑆+ 0.006𝑀 − 0.02𝑃𝑂𝐿 − 2.661𝑞𝐶5 
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and the receptor the same for the molecular weight. The positive coefficients of MW explain 
that any decrease molecular weight of the compounds causes a decrease in the biological 
activity. 
It can be observed that high coefficients of Ligand efficiency LE. Thus, high LE lead 
to increasing aromatase inhibitory activity high LE prefers compounds that gain to escape 
the affinity-biased selection and optimization towards larger ligands. The focus should be 
directed towards the generation of compounds that use their atoms most efficiently. 
In model, the positive coefficient of TPSA indicates that the substituents which 
increase molecular polar surface area will lead to increased activity. This relates to the 
molecular transport through membranes Suggested that a decrease in the permeability might 
decrease the activity. 
It can be observed that high coefficients of atomic charges on atoms N2, C4 and C5 
(qN2, qC4 and qC5 respectively). Thus, high negative charges lead to increasing aromatase 
inhibitory activity. 
The charges allowed a physical explanation and electronic molecular properties 
contributing to aromatase inhibitory potency as the electronic character related directly to 
the electron distribution of interacting molecule at the site active. 
 
Once the equation is obtained, it is important to determine its reliability and 
significance. The validation of the equation is done by cross-validation /leave-one out 
method. The results are shown below. 
Table IV.3. Cross-validation parameter. 
PRESS SSY PRESS/SSY SPRESS R2cv R2adj 
0.202 11.072 0.018 0.149 0.982 0.953 
 
Also, for reasonable QSAR model the PRESS/SSY ratio should be lower than 0.4 [26]. 
The data presented in (Table.IV.3) indicate that for the developed model this ratio is 0.018. 
Our result of R2cv and R2adj for this QSAR model has been to be 0.982 and 0.953 
respectively. The high value of R2cv and R2adj are essential criteria for the best qualification 
of the QSAR model. 
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One can also use the Spress parameter that reflects the error changes predictions. 
Developed QSAR models have low values of Spress (<0.200) indicating that the model has 
small residual value between observed and predicted biological activities. We can see from 
the Table IV.3 that all residual values less than twice of standard error of estimate (0.149) 
therefore There, aren’t any outliers. 
In order to confirm our results, we have estimated the aromatase inhibitory activity 
pIC50 of training sets using the model expressed by equation. and compared them with the 
observed values. The data presented in (Table IV.4) show that the observed and predicted 
activities are very close each other.  
The plots for this model show to be more convenient with R2= 0.9914. It indicates that 
the model can be successfully applied to predict the aromatase inhibitory activity of these 
compounds. 
To investigate the presence of a systematic error in developing the QSAR models. The 
residuals of predicted values of the biological activity pIC50 were plotted against the 
experimental values as shown in (Figure.IV.3). 
 
The propagation of the residuals on both sides of zero indicates that no systemic error 
exists. As suggested by Jalali-Heravi and Kyani. [27,28] It indicates that this model can be 
successfully applied to predict the aromatase inhibitory activity of this class of molecules. 
The correlation matrix for pIC50 and selected descriptors to build the QSAR model 
is shown in (Table IV.4) shows that the distribution coefficient Log P and the Ligand 
efficiency LE are parameters important in the correlation between selected descriptors and 
the aromatase inhibitory activity. 
The parameters used in the Model are almost Independent which can be seen from 





Table IV.4 Experimental and predicted aromatase inhibitory activities (pIC50) of 









1 5.470 5.599 -0.129 13 5.330 5.276 0.054 
2 5.040 5.129 -0.089 14 4.920 4.903 0.017 
3 5.380 5.227 0.153 15 4.870 4.782 0.088 
4 5.630 5.652 -0.022 16 4.820 4.817 0.003 
5 4.940 5.002 -0.062 17 5.340 5.298 0.042 
6 5.330 5.309 0.021 18 4.960 4.993 -0.03 
7 5.100 4.928 0.172 19 4.830 5.025 -0.19 
8 5.650 5.655 -0.005 20 4.890 4.871 0.019 
9 8.100 8.042 0.058 21 4.860 4.770 0.090 
10 5.290 5.342 -0.052 22 4.510 4.416 0.094 
11 4.960 5.039 -0.079 23 4.780 4.95754 -0.17 








Figure. IV. 2. Scatter Plot between the Observed and Predicted Activities of Model of a- 
training set b- test set for the test set. 
 
 
Figure IV.3. Plots of the residual values against the experimentally observed. 
The proposed model passed all the tests for the predictive ability . 
The results obtained show that the predicted values (Table IV.4) are very close to the 
observed values (figureIV.2.b) the value of R² is equal to 0.851 which confirms that model 
adequately describes the relationship between pIC50 predicted and observed model. Further 













Table IV.5. Correlation matrix of the fourteen selected descriptors 
  
 
 pIC50 S M logP EH Pol Ref LE ELUMO qN1 qN2 qC4 qC5 TPSA ABS 
pIC50 1               
S 0.26 1              
M 0.26 0.90 1             
logp 0374 0.676 0.41 1            
EH 0.258 0.180 0.45 0.529 1           
Pol 0.224 0.800 0.80 0.570 0.07 1          
Ref 0.064 0.404 0.36 0.387 0.180 -0.83 1         
LE 0.776 0.413 0.45 0.314 0.063 -0.46 0.34 1        
ELUMO 0.288 0.095 0.12 0.168 0.474 0.151 0.302 0.003 1       
qN1 0.555 0.267 0.09 0.230 0.22 0.202 0.21 -0.40 0.348 1      
qN2 0.094 0.356 0.20 0.125 0.14 -0.14 0.04 0.128 0.166 0.500 1     
qC4 0.1 0.27 0.2 0.297 0.07 0.199 0.07 -0.01 0.010 0.22 0.064 1    
qC5 0.071 0.044 0.16 0.472 0.55 -0.08 0.18 -0.06 0.335 0.397 0.267 -0.1 1   
TPSA 0.218 0.148 0.21 0.228 0.51 0.071 0.02 -0.19 0.700 0.06 0.143 -0.2 0.205 1  





Table IV.6 Observed and predicted activity of test compounds 
Compounds pIC50 exp. pIC50 pred. 
25t 4.99 4.87 
26t 5.64 5.87 
27t 4.8 4.74 
28t 4.87 4.96 
29t 5.87 6.1 
30t 5 5.11 
 
Table IV.7. Predictive power results for the external test set; Golbraikh and Tropsha 
criteria 
Golbraikh and Tropsha’s criteria 𝑹𝒑𝒓𝒆𝒅𝟐  K K’ 𝑹°𝟐 𝑹′°𝟐 𝑹𝟐 − 𝑹°𝟐𝑹𝟐  𝑹𝟐 − 𝑹′°𝟐𝑹𝟐  |𝑹𝟎𝟐 − 𝑹°′𝟐| 
0.851>0.6 0.982>0.85 1.017<1.15 
0.972r 
is close to R2 
0.952 is 
close to R2 
 
-1.04<0.1 -0.11<0.1 0.02< 0.3 
 
From the Table IV.5 it is obvious that the predicted responses of all the test compounds 
are in good agreement with their corresponding observed responses as well as ideal fit is 
attained produced by plotting a graph (Figure.IV.3) by correlating observed activity versus 
predicted activity of the test set compounds, the squared correlation coefficient is calculated 
as 0.923. 
The predictive abilities of the best MLR was tested (Table IV.6) using the Golbraikh–
Tropsha criteria and the R2pred test (see Model Validity section). All the calculated parameters 
indicated the model showed a good predictive power. 
Analyzing the results of the external test set listed in Table IV.8, It could be observed 
that all the Golbraikh–Tropsha criteria were fulfilled. 𝑟𝑚2   value of 0.556 whereas values of average 𝑟𝑚2 of 0.581 and ∆𝑟𝑚(𝑡𝑒𝑠𝑡)2  of 0.042 extend 





Once the QSAR model formulated and validated properly. Its utility is to predict the 
biological responses of the compounds which are generated by combinatorial deign and 
experimentally non-investigated. 
 
Table IV.8Validation characteristics of developed model according to r2m metrics and 
Concordance correlation coefficient 
rm2 parameter Concordance correlation 
coefficient 𝒓𝒎𝟐  𝑟𝑚′2 𝛥𝑟𝑚(𝑡𝑒𝑠𝑡)2  𝑟𝑚(𝑡𝑒𝑠𝑡)2̅̅ ̅̅ ̅̅ ̅̅ ̅̅  CCC 
0.556>0.5 0.581 0.042<0.2 0.568>0.5 0.946>0.85 
 
 
4. CONCLUSION  
In this study SW-MLR was used to develop linear QSAR model for prediction of 
aromatase inhibitory activity of triazole derivatives. The built model displayed good 
correlations between the structure and activity of the studied compounds. The model was 
validated using LOO cross-validation and external test set. The built model has a good self-
and external-predictive power. Based on QSAR model results coefficients of Ligand 
efficiency LE atomic net charges (qN1) and partition coefficient octanol/water (log P), were 
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MOLECULAR DOCKING STUDIES 
AND IN SILICO ADMET OF NEW 
SUBSTITUTED 1.2.3 TRIAZOLE 






1. INTRODUCTION  
This study is precisely on aromatase inhibitors as these inhibitors play a central role in 
the treatment of breast cancer [1]. Estrogen is important and promotes the growth and 
survival of normal and cancer epithelial cells. The chemical compound estrogen binds to the 
estrogen receptor (ER) and the activation of the cell progression takes place. The active 
estrogen receptor tends to bind with promoter gene present in the nucleus, which regulates 
the gene activity and translates the protein [2]. The activated receptor in turn binds to gene 
promoters in the nucleus and activates many other genes [3]. The activated gene products 
are thereby responsible for cell division, inhibition of cell death, new blood vessels formation 
and protease activity. Rapid expression of estrogen receptor is found at earlier stages of 
breast cancer. Nearly 70% cancer mainly depends on the over-expression of estrogen 
receptor [4,5]. 
these inhibitors have an azole hetero ring containing a sp2 nitrogen atom which binds 
to the heme iron atom of aromatase to show activity inhibitory. as part of our search for new 
aza-hetrocyclic derivatives as aromatase inhibitors. [6,7] 
The results revealed that 1,2,3-triazole analog of letrozole showed equipotent activity 
to the parent compound. In addition, the 1,4-disubstituted-1,2,3- triazole was shown to be 
the most potent compound (IC50 = 1.36 µM) among the tested 1,4-disubstituted-1,2,3-
triazole series. However, the interaction mode of the 1,4-disubstituted-1,2,3-triazole series 
with the target enzyme remains to be explored. [ 8,9]. 
 
In the present work, the potential of the aromatase inhibitors, letrozole and 1.2.3 
triazole Derivatives in the treatment of breast cancer has been analyzed using computational 
approach. 
Molecular docking is a computational procedure that attempts to predict the 
noncovalent binding of a macromolecule (Receptor) obtained from data banks or MD 
simulations, etc. with a small molecule (Ligand) as a lead for further drug development. The 
lead candidates can be found using a docking algorithm that tries to identify the optimal 
binding mode of a small molecule to the active site of a macromolecular target. 
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The docking of aromatase inhibitors and 1.2.3 triazole with human placental aromatase 
cytochrome P450 reveals the role of amino acid, not only at the active site but also at the 
molecular or atomic level interaction of these compounds. 
 The ADMET properties of drugs, together with its pharmacological properties are 
conventionally viewed as a part of drug development. The best ligands after docking analysis 
were subjected to predict.  
2. MATERIAL AND METHODS 
2.1. Enzyme Structure 
The X-ray crystal structures of human placental aromatase cytochrome P450 in 
complex with androstenedione (4-ANDROSTENE-3-17-DIONE C19H26O2 
AEMFNILZOJDQLW-QAGGRKNESA-N) (PDB ID:3EQM) [10]. were downloaded from 
RCSB Database (http://www.rcsb.org/pdb). 
Computational analysis was carried out on chain A of 3EQM.  
3EQM is a three-dimensional structure with EC Number: EC#: 1.14.14.14, chains (A), 
resolution 2.90 Å, and R-value 2.44.  
After the download we simplified one of the two chains and we eliminated the water 
molecules and the cofactors 
2.2 Ligand Structures 
All ligand structures of 1,2,3-triazole derivatives [11] were optimized by using MM+ 
molecular modeling and the semi-empirical AM1 method, both of which are implemented 
in HyperChem 7.0 software (version 7.0, Hypercube, USA, http://www.hyper.com). For 
these calculations, the Polak–Ribiere conjugate gradient algorithm was employed, with the 
RMS gradient set to 0.0001 kcal/(Å.mol). 
2.3 Cavity prediction 
All cavities or the potential ligand binding site of 3EQM was predicted using MVD is 
given in Fig.V1. A cavity which has an important volume 304.64 Å3 was predicted and used 
in our study. The binding site was set inside a restriction sphere of 15 radiuses with the 





Figure.V.1. The five cavities MVD-detected cavities 
2.4 Molecular docking simulation 
In the present investigation, we make use of a docking algorithm called MolDock.  
MolDock is based on a new hybrid search algorithm, called guided differential evolution. 
The guided differential evolution algorithm combines the differential evolution optimization 
technique with a cavity prediction algorithm. The use of predicted cavities during the search 
process, allows for a fast and accurate identification of potential binding modes (poses).  
We used MVD because it showed higher docking accuracy than other stages of the 
docking products (MVD: 87%, Glide: 82%, Surflex: 75%, FlexX: 58%) in the market 
[12,13]. Molecular docking technique was employed to dock some novel derivatives of 
1,2,3- triazole designed L1-L29 (fig.V.3) against p450 receptor 3EQM using MVD to locate 
the interaction between various compounds and active site of aromatase.  
MVD requires the receptor and ligand coordinates in either Mol2 or PDB format. Non 
polar hydrogen atoms were removed from the receptor file and their partial charges were 





Figure V.2. Secondary structure of the target 
In the docking simulations with MVD, the pose with the minimum MolDock score 
value was selected as the best solution, and for creating two dimensional representations of 
interactions between ligand and enzyme, LigPlot+ software was used. 
Molecular docking was performed using MolDock docking engine of Molegro 
software [24]. The binding site was defined as a spherical region which encompasses all 
protein atoms within 15.0 Ao of bound crystallographic ligand atom (dimensions X (85.67 
A°), Y (51.14 A°), Z (43.73 A°) axes, respectively). Default settings were used for all the 
calculations.  







   
 
    
    
    
    
 
Figure.V.3. Chemical structures of the 1.2.3 triazole derivatives. 
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Docking was performed using a grid resolution of 0.3 Ao and for each of the 10 
independent runs; a maximum number of 1500 of interactions were executed on a single 
population of 50 individuals. 
2.5 Molecular Property Prediction:  
Molecular descriptors and drug likeliness properties of compounds were analyzed 
using the tool Molinspiration server (http://www.molinspiration.com), based on Lipinski 
Rules of five [14]. 
According to Lipinski's rule of five, poor absorption or permeation is more likely when 
there are more than 5 H-bond donors, 10 H-bond acceptors, the molecular weight is greater 
than 500 Da and the calculated LogP (CLogP) is greater than 5 (or MlogP>4.15)[16].. 
Moreover, good bioavailability is more likely for compounds with ≤10 rotatable bonds 
(nrotb) and total polar surface area (TPSA) of ≤140 Å (rule of Veber) [15]. 
2.6  Prediction of ADMET properties: 
The pharmacokinetic properties such as Absorption, Distribution, Metabolism, 
Excretion and the Toxicity of the compounds can be predicted using the ADMETSAR 
(http:// www.admetexp.org) database. However, BBB (Blood-Brain Barrier) penetration, 
HIA (Human Intestinal Absorption), Caco-2 cell permeability and Ames test were calculated 
using the ADMETSAR.  
In the ADMETSAR, web-based query tools incorporating a molecular build-in 
interface enable the database to be queried by SMILES and structural similarity search. It 
provides the latest and most comprehensive manually curated data for diverse chemicals 
associated with known ADMET profiles (ADMETSAR@LMMD) [16]. 
3. RESULTS AND DISCUSSION 
3.1 Molecular docking studies 
Molecular docking of 1,2,3-triazole derivatives to the aromatase enzyme was 
performed to investigate their binding interactions and to explore their binding modes. 
Moreover, our lead compound was also docked in order to investigate its binding pattern to 
the aromatase active site. The Protein-Ligand interaction plays a vital role in structural based 




In this present study, we have identified 1,2,3-triazole derivatives, by means of 
molecular docking studies to be a novel and likely more potent inhibitor of aromatase than 
one of third-generation aromatase inhibitors (letrozole).  
The results obtained show that all the ligands have interactions with the 3EQM at the 
level of the cavity 1, the FigureV.4. Explain Pose organize between human placental 










Figure.V.4 Pose organize between human placental aromatase cytochrome P450 and most 





Table V.1.: Docking Results of 3EQM enzyme with of the compounds studied and 
Letrozole 







1 -114.854 -120.09 -2.44 3.32 
2 -137.39 -141.36 -9.73 1.25 
3 -142.30 -156.73 -5.02 11.26 
4 -143.99 -151.37 -5.69 5.56 
5 -138.84 -138.25 -6.11 -3.94 
6 -134.71 -137.38 -3.56 0.69 
7 -103.71 -110.53 -2.82 6.39 
8 -118.15 -124.06 -5.57 3.96 
9 -152.84 -155.29 -6.87 2.91 
10 -152.71 -150.93 -1.74 6.57 
11 -132.77 -146.23 -1.10 10.50 
12 -165.8 -169 -5.08 1.66 
13 -165.01 -178.04 -7.92 6.44 
14 -179.89 -189.90 -5.22 6.94 
15 -130.14 -140.23 -4.70 8.91 
16 -141.25 -160.6 -5.70 15.11 
17 -98.28 -106.75 -4.08 5.96 
18 -109.72 -117.338 -6.88 6.9 
19 -127.61 -134.97 -6.68 5.96 
20 -122.64 -136.7 -5.40 12.90 
21 -117.89 -133.05 -4.88 13.50 
22 -127.59 -143.45 -6.94 14.02 
23 -139.8 -152.16 -0.92 9.91 
24 -131.99 -147.49 -6.57 9.05 
25 -121.09 -120.45 -5.89 -2.36 
26 -146.98 -156.76 -6.65 6.92 
27 -121.91 -130.3 -6.61 -0.05 
28 -152.2 -157.85 -5.85 3.64 
29 -151.3 -179.28 -3.10 16.21 
letrozole -125.71 -130.48 -1.61 3.55 
 
Based essentially on the comparison between the energies obtained using Mol Dock 
Score and the results obtained during molecular docking, it is noted that the energies of the 
complexes formed by ligands L14, L13, L12 Are lower compared to other complexes. -





The energy map of 3EQM that might contribute in steric interaction favorable (green 
color), hydrogen acceptor favorable (turquoise color), hydrogen donor favorable (yellow 
color) and electrostatic potential of 3EQM (red and blue color) with the ligand viz. Letrozole, 
L14. L13. and L12 are shown in Fig V.5, respectively. 
  
  
Figure.V.5 Energy map of most active compounds and Letrozole in the binding cavity 
of 3EQM 
 
The main type of interaction for the letrozole atom control is the steric interaction. 
While The three compounds studied. The main interaction its hydrogen acceptor. Table V.2 




Table V.2. Summary of residues interacting with the aromatase inhibitors. 
 

































































































Ser478………….O 2.83 -0.83 
 
 





















Figure.V.6 Hydrogen bonding and steric interactions between aromatase receptor and 
most active compound 
 The docked structure of L13 indicated that the CN group was extensively hydrogen 
bonded to the Arg115, and Met374 residues with bond distances of 3.14, and 3.34 A ° 
respectively (Table V.2.) (Fig V. 6). Another oxygen atom of compound L13, was also 
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involved in a hydrogen bond interaction with the Ser478 residue of the 3EQM. Additionally, 
Thr310, Ala306, Trp224, and Ile133 residues of the 3EQM displayed steric interactions with 
compound L13.  
The stereo view of the docked complex indicated that both N atom (triazole cycle) of 
compound 12 interacted with the 3EQM by means of steric interactions (Fig.V. 6). The O 
atom in L12 was hydrogen bonded to the Ser 478 residues with bond distances of 2.83 A 
°tableV.2. Although, other H-bond interactions exist, these hydrogen bonds are relevant for 
inducing intrinsic activity towards highly selective and aromatase specific inhibitory 
property.  
In particular two of the “rules” state that drugs should contain no more than 5 hydrogen 
bond donors and 10 acceptors. These rules arise because of the need to balance absorption 
and distribution properties with binding specificity within a relatively small drug molecule. 
that two aromatic rings along with two hydrogen bond donors are important 
pharmacophores for strong aromatase inhibition. (compound 13) Moreover, the importance 
of hydrogen bonding in aromatase inhibition was suggested by Neves et al. [17].  
The distances measured between the 3 ligands and the amino acids of the cavity 1 are 
cited in the table V.2. 
The distances between the residues of the active site and the L14, L12, L13 vary 
between 2.09 Å and 3.20 Å, in this case it can be observed that according to Anne Imberty 
[18]., the interactions having distances between 2.5Å and 3.1Å Are considered as strong, 
those with distances between 3.1Å and 3.55Å are assumed to be average and when their 









Figure V.7: Ligplot + results showing the interactions of most active compounds and 




To confirm our results, we have shown in the figure.V.7 the different interactions 
between the residues of the active site and the 4 ligands (fourth: letrozole ligand). 
The most of amino acid residues in hydrophobic active site were involved in affinity 
hydrophobic bonding interactions of ligand [18]. (Figure V.8 et V.9). This figure shows 
hydrophobic and electrostatic bonding between the most compounds L14.L13.and L12 and 
letrozole with 3EQM. 
According to the figure It was observed that Letrozole occupied hydrophobic pocket 
with the residues His480, glu302, phe221, Val373 and Val370. and are the same residues as 









Figure.V.8 Hydrophobic bonding interactions between human placental aromatase 








Figure.V.9 electrostatic bonding interactions between human placental aromatase 
cytochrome P450 and most active compounds and Letrozole 
The residues comprising the catalytic cleft are Ile 305, Ala 306, Asp 309 and Thr 310 
from the I-helix, Phe 221 and Trp 224 from the F-helix, Ile 133 and Phe 134 from the B-C 
loop, Val 370, Leu 372 and Val 373 from the K-helix–b3 loop, Met 374 from b3, and Leu 
477 and Ser 478 from the b8–b9 loop). from the results it is found that all three ligands 
L14, L13 and L12 interact with the aromatase catalytic site residues. 
The structure of most main content of 1,2,3- triazole was nonpolar, so this gave an 
advantage to hydrophobic for binding inside chains as receptor active site. The most active 
compounds have similar role binding with letrozole that has been proven as aromatase agent 
and occupied in cavity 1 of human placental aromatase cytochrome P450 toward 
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hydrophobic binding with aromatic ring, aliphatic chain and carbonyl group. Aromatic ring 
was important for binding. 
3.2 Molinspiration Calculation 
The CLogP (octanol / water partition co efficient) was calculated by the methodology 
developed by Molinspiration as a sum of fragment-based contributions and correlation 
factors. The molecular descriptors of best five compounds were tested to Lipinski’s rule of 
five, interestingly all the ligands which we selected have molecular weight in the range of 
416 – 467 (< 500). Low molecular weight drug molecules (< 500) are easily transported. 
Diffuse and absorbed as compared to heavy molecules[19]. 
 
Table V.3.In-silico prediction of ADME properties of compounds L14.L13 and L12. 
Compound Mi logP c TPSA f MW d HBA a HBDb N ROTe 
L14 6.22 87.54 467.54 6 0 7 
L13 4.49 96.74 421.46 7 0 7 
L12 4.18 111.13 416.44 7 0 6 
a Number of hydrogen bond acceptors b Number of hydrogen bond donor’s c Calculated octanol/water partition coefficient d Molecular 
weight. f Topological polar surface area e Number of rotatable bonds. 
 
Molecular weight is an important aspect in therapeutic drug action, if it increases 
correspondingly, which in tum affects the drug action [20]. Number of hydrogen bond 
acceptors (O and N atoms) and number of hydrogen bond donors (NH and OH) in the tested 
compounds were found to within Lipinski limit range from 5-7 and less than 10 and 5 
respectively. 
Lipophilicity (log P value) and TPSA values are two important properties for the 
prediction of per oral bioavailability of drug molecules [21]. Permeability property of 
compounds were analyzed, the calculated log P value of L13 and L12 compounds was 4.49 
and 4.18 (< 5). respectively. In contrast, the oral bioavailability of L14 is questionable where 
the mlogp was outranged. Which is the acceptable limit for the drugs to be able to penetrate 
through bio membranes. 
 Topological polar surface area TPSA was calculated as described by Veber et al[22]. 
O- and N-centere dpolar fragment were considered. TPSA has shown to be a very good 
descriptor characterizing drug absorption. Including intestinal absorption, bioavailability, 
Caco-2 permeability and BBB penetration. The highest degree of lipophilicity was found 
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with all the compounds, which are an indication for good lipid solubility that will help the 
drug to interact with the membranes. TPSA was calculated from the surface areas that are 
occupied by oxygen and nitrogen atoms and by hydrogen atoms attached to them. [23]. Thus, 
the TPSA is closely related to the hydrogen bonding potential of a compound. In our study, 
all ligands exhibited 86- 111 value of TPSA, indicates good bioavailability by oral route. 
Good bioavailability is more likely for compounds with ≤10 rotatable bonds and TPSA of ≤ 
140 Å. As the number of rotatable bonds increases, the molecule becomes more flexible and 
more adaptable for efficient interaction with a particular binding pocket. Interestingly all the 
four compounds have 6-7 rotatable bonds and flexible. 
3.3 ADMET properties 
As derived from admet SAR server, reveal that L14 and L13 had better Human 
Intestinal Absorption (HIA) score than the control letrozole. Greater HIA denotes that the 
compound could be better absorbed from the intestinal tract upon oral administration. The 
results obtained for BBB penetrability greatly agreed with structures of the studied 
compounds. The compound has a less polar sesquiterpene lactone, was predicted to cross 
BBB, this is their order (L12, L13, L14 and letrozole). When it comes to predicting the efflux 
by P-glycoprotein P-gp all the compounds came out as a non-substrate and non-inhibitor of 
P-gp similar to our control molecule. AMES toxicity test is employed to know whether a 
compound is mutagenic or not. Similar to the control molecule, the l14 and l12 test ligands 
displayed negative AMES toxicity test, which means that the ligands are non-mutagenic. 
Carcinogenic profile also revealed that the ligands were non-carcinogenic similar to the 
control molecule. 
The next important parameter is cytochrome P450 (CYP), which is known as isozymes 
group and it is involved in the metabolism of drugs, fatty acids, steroids, bile acids and 
carcinogens. Notwithstanding, some of the cytochrome P450 isoforms could be inhibited by 
one or more of the tested compounds. 
 Considering the cytochrome P450 (CYP) analysis, the major limitation of letrozole is 
its CYP450 3A4 substrate nature, lead to high drug–drug interaction and interruption in the 

















L14 L13 L12 letrozole 
Result Probability Result Probability Result Probability Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9732 BBB+ 0.9564 BBB+ 0.9746 BBB+ 0.9737 
Human Intestinal 
Absorption 
HIA+ 1.0000 HIA+ 1.0000 HIA+ 0.9971 HIA+ 0.9965 
Caco-2 Permeability Caco2+ 0.5053 Caco2+ 0.5369 Caco2+ 0.5178 Caco2+ 0.6347 
Distribution 
Subcellular localization Mitochondria 0.8808 Mitochondria 0.8460 Mitochondria 0.8475 Mitochondria 0.7175 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.7090 Non-substrate 0.6527 Non-substrate 0.7134 Non-substrate 0.7898 
CYP450 2D6 Substrate Non-substrate 0.8224 Non-substrate 0.8163 Non-substrate 0.8220 Non-substrate 0.9116 
CYP450 3A4 Substrate Non-substrate 0.5248 Substrate 0.5232 Non-substrate 0.5470 Non-substrate 0.6843 
CYP450 1A2 Inhibitor Inhibitor 0.6730 Inhibitor 0.5711 Inhibitor 0.6088 Non-inhibitor 0.8374 
CYP450 2C9 Inhibitor Inhibitor 0.6980 Non-inhibitor 0.5246 Inhibitor 0.5946 Non-inhibitor 0.9071 
CYP450 2D6 Inhibitor Non-inhibitor 0.8416 Non-inhibitor 0.8758 Non-inhibitor 0.8549 Non-inhibitor 0.9230 
CYP450 2C19 Inhibitor Inhibitor 0.7239 Non-inhibitor 0.5319 Inhibitor 0.6457 Inhibitor 0.8993 
CYP450 3A4 Inhibitor Inhibitor 0.5000 Non-inhibitor 0.5256 Non-inhibitor 0.5834 Inhibitor 0.6451 
Toxicity 
Human Ether-a-go-go-
Related Gene Inhibition 
Weak inhibitor 0.6477 Weak inhibitor 0.5000 Weak inhibitor 0.5267 Weak inhibitor 0.9261 
AMES Toxicity Non AMES 
toxic 
0.5678 AMES toxic 0.5240 Non AMES 
toxic 
0.5270 Non AMES toxic 0.6371 
Carcinogens Non-
carcinogens 
0.8990 Non-carcinogens 0.9274 Non-
carcinogens 
0.9169 Non-carcinogens 0.8926 







The formation of a stable complex depends on the binding of the ligand in the active 
site. Our results, show that there are several interactions between ligands L14, L13 and 
L12 with the residues of the active site, which means the formation of complexes Stable, 
and thereafter, better binding of these ligands at the active site. 
The highest degree of lipophilicity was found with all the compounds, which are an 
indication for good lipid solubility that will help the drug to interact with the membranes. 
The analysis of molecular docking gives place at the prospective identification of ligands. 
The molecules L14, L13and L12 have the potential to inhibit the activity of 3EQM. The 
molecules L14, L13 and L12 demonstrate the better result in in-silico analysis. Moreover 
L13 has shown good hydrogen bonding which was not observed in our prototype Letrozole. 
All the designed ligands have shown no trace of carcinogenic.  
Hence it has been predicted that all our designed ligands (Especially L12) can possibly 
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In this work, we applied the methods of Computational Approaches for Drug Design 
and Discovery, this study involved: 
 In silico studies on structure activity relationships of substituted 1,2,3-
triazole as aromatase inhibitor. 
 QSAR model for predicting the aromatase inhibition activity of 1,2,3-
triazole derivatives. 
 Molecular docking studies and in silico ADMET of new substituted 1,2,3-
triazole derivatives for anti-breast cancer activity. 
We applied many methods of computational chemistry in this study. Quantum 
mechanics methods were used in the study of chemical reactivity of triazole and their 
derivatives, with methods: PM3, Ab initio/ (HF / 6-311 
++
 G (d, p)) and DFT (B3LYP / 6-
311 
++ 
G (d, p)), whose purpose is to determine the structural, electronic and energetic 
parameters associated with the molecules studied. 
The efficiency of these methods used was confirmed by the comparison of the 
structural parameters between the results obtained by Ab initio and DFT theoretical 
methods. The nature of the substituent type (donor, acceptor) influences the core electronic 
and energetic parameters. Indeed, this study allows us to predict the of triazole derivatives. 
The qualitative study of the structure-properties relationship was carried out on the 
22 compounds. The molecules used in this study have pharmacological properties. The 
nature of the groups that bind to the basic nucleus of the molecules studied affects their 
physicochemical properties and consequently their pharmacological properties. 
Molecular properties such as membrane permeability and oral bioavailability are 
usually associated with some basic molecular descriptors, such as log P (partition 
coefficient), molecular weight (MW), and the acceptors and donor for hydrogen bonding in 






In the pursuit of robust aromatase inhibitors, 1.2.3-triazole derivatives were 
employed in quantitative structure activity relationship (QSAR) study using multiple linear 
regression (MLR). The results demonstrated good predictive ability for the MLR model. 
After dividing the dataset into training and test set. The models were statistically robust 
internally (R
2
 = 0.982) and the model predictability was tested by several parameters, 
including the external criteria (R
2
pred = 0.851. CCC = 0.946). Insights gained from the 
present study are anticipated to provide pertinent information contributing to the origins of 
aromatase inhibitory activity and therefore aid in our on-going quest for aromatase 
inhibitors with robust properties. 
As well as our interest was focused on the study of the interactions between 
the3EQM enzyme and the triazole derivatives, to better understand the mechanism of 
inhibition of these enzymes. 
First, we tested molecular docking performances by Mol Dock Score and non-
binding distances (Hydrogen and Steric). 
The discussion was based essentially on these two parameters to explain the 
formation of the complexes (Enzyme-substrate), and subsequently the ligand binding at the 
active 3EQM site. 
The study showed that the three ligands L12, L13 and L14 are the best inhibitors of 
3eqm, these ligands possess the lowest energies compared to other seven with respect to 
the ligand of reference letrezole. 
The application of Lipinski rules on the studied three ligand (L12.L13 and L14) 
shows that all these compounds, theoretically, will not have problems with oral 
bioavailability. 
The last part of this work allowed us to learn about the possible pharmacokinetic 
properties of absorption, digestion, metabolism and excretion of the three ligands. 
The ADME prediction also showed very encouraging results. Hence, these 
compounds may be tested in vitro as future aromatase inhibitors. 
Abstract 
Breast cancer is the most common type of female cancer. One class of hormonal therapy for breast 
cancer drugs -non steroidal aromatase inhibitors- are triazole analogues. In this work a fundamental 
and original research was made on the molecule of triazole heterocyclic, whose the aim is to 
predict the reactivity and biological activity studied of the compound. It is based on different 
computational and approaches used in computer aided -drug-design. (SPR, QSAR, molecular 
docking, ADMET). 
A study of structure – property relationships (SPR) for 1,2,3 triazole derivatives has been carried. 
A linear quantitative structure activity relationship model is obtained using Multiple Linear 
Regression (MLR) analysis as applied to a series of triazole derivatives with inhibitory activity of 
the aromatase. The accuracy of the proposed MLR model is illustrated using the following 
evaluation techniques: cross validation, and external test.  
Docking process, the interaction and binding of ligands – protein were done and visualized using 
software Molegro Virtual Docking. 
Molinspiration and ADMETSAR web servers used to calculate ADMET and physicochemical 
properties of the target compounds respectively. 
The results are reported and discussed in the present investigation. A close agreement with 
experimental results was found which improves the affinity of the present work. 
 




Le cancer du sein est le type de cancer le plus répandu chez les femmes. Une classe 
d'hormonothérapie pour les médicaments anticancéreux - les inhibiteurs non stéroïdiens de 
l'aromatase - sont les analogues du triazole. Dans ce travail, une recherche fondamentale et 
originale a été faite sur la molécule de triazole hétérocyclique, dont le but est de prédire la 
réactivité et l'activité biologique  des composés étudiés. Il repose sur des différentes approches 
informatiques et des calculs utilisés dans la conception de médicaments assistée par ordinateur. 
(SPR, QSAR, amarrage moléculaire, ADMET). 
Une étude des relations structure-propriété (SPR) pour les dérivés du 1,2,3-triazole a été réalisée. 
Un modèle quantitative linéaire de la relation structure-activité a été obtenu à l'aide de l'analyse de 
la régression linéaire multiple (RLM) appliquée à une série de dérivés de triazole ayant une activité 
inhibitrice de l'aromatase. La précision du modèle proposé (RLM) est illustrée à l'aide des 
techniques d'évaluation suivantes : validation croisée et le  test externe. 
Le processus de docking, l'interaction et la liaison des ligands - protéines ont été réalisés et 
visualisés à l'aide du logiciel Molegro Virtual Docking.  
Les serveurs Web Molinspiration et ADMETSAR sont utilisés pour calculer les propriétés 
ADMET et les propriétés physicochimiques des composés cibles, respectivement. 
Les résultats sont rapportés et discutés dans la présente enquête. Un accord étroit avec les résultats 
expérimentaux a été trouvé, ce qui améliore l’affinité du travail actuel. 
 
Mot clé: 1,2,3-triazole, inhibiteur de l'aromatase, théorie de la densité fonctionnelle, QSAR, MLR, 
ADMET, docking moléculair. 
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